 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 1 of 84 
 
 
 
NCT number - [STUDY_ID_REMOVED] 
 
Vibrant Ltd. 
Study Protocol 
 
Study number: V-250 
Protocol number: 250CLD  
Protocol Date: Oct 7th  , 2018  
Rev. 02 
 
A prospective, Multicenter, Randomized, 
Single Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the 
Treatment of Chronic Idiopathic 
Constipation (CIC) 
 
Confidentiality statement: 
The following confidential information is the proper ty of Vibrant Ltd.  As long as the information 
contained in this protocol has not been published, it may only be used when permission has been 
obtained from Vibrant Ltd. in writing.  It is not permitted to make  reproductions of all or sections 
of this protocol.  Commercial use of the inform ation is only possible w ith the permission of the 
proprietor and is subject to a license fee.   
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 2 of 84 
 
 
 
1. Sponsor 	Statement 	of	compliance 	
 
The sponsor of this study, Vibrant Ltd., manufact urer of the investiga tional device, legally 
represented by Lior Ben-Tsur, Chief Ex ecutive Officer, stat es the following: 
 
a. to assume responsibility related to the clinical investigation; 
b. that the treatments used to perform the c linical study are adequa te for the device under 
investigation; 
c. that the clinical study, as for the responsibility of the manu facturer, will be conducted in 
conformance with: 
 
The Federal Food, Drug, and Cosmetic Act, as am ended, and regulations promulgated thereunder 
(“the Act”) and the United States Food and Dr ug Administration (“FDA” ) regulations governing 
the protection of human subjects  and regulations governing clinic al investigators, The World 
Medical Association Declaration of Helsinki, titl ed “Ethical Principles for Medical Research 
Involving Human Subjects”, ICH/GCP guidelines, Applicable relevant national legislation, 
HIPAA as defined in 45. C.F.R. section 164.501 or  relevant national equivalent and following 
revisions or other analogous inte rnationally recognized standards,  to be specified, and only after 
the approval, by the competent Ethics Committee, of the investigational protocol, the informed 
consent and the documentation required  by the above ment ioned standards; 
 
  
Print Name:  Signature:   Date: 
 
 
 
Lior Ben-Tsur                         -------------------- ---------           ----------- ------------- 
      
 
     
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 3 of 84 
 
 
 
2. Investigator 	Agreement: 		
Prior to participation in this study, a written approval must be obtaine d from the In stitutional 
Review Board, and copy should be provided to th e Sponsor, Vibrant Ltd., or their authorized 
representatives, along with the Institutional Review Board appr oved Informed Consent Form.   
 
The Principal Investigator must also: 
 Conduct the study in accordance with the study protocol, the Investigator Agreement, 
Declaration of Helsinki, Good Clinical Practices, international harmon ized standards for 
clinical investigation of medical devices (Title  21 of the Code of Federal Regulations (21 
CFR), part 812 (Investigational Device Exempt ions), the laws and regulations of the 
countries where the study will take place, i ndemnity/insurance requirements and any other 
applicable regulations.   
 Agree to participate in an appropriate traini ng program as part of the study initiation. 
 Assure that informed consent is obtained fro m each subject prior to enrollment, using the 
Institutional Review Bo ard approved form.   
 Assure that the study is not commenced until  Institutional Review Board approval has 
been obtained. 
 Provide all required data and agree to sour ce document verification of study data with 
subject’s medical records.   
 Allow staff of the Sponsor and its authorized representatives,  as well as representatives 
from regulatory agencies, to review, inspect and copy any documents pertaining to this 
clinical investigation.  
 
The Principal Investigator (PI) ma y delegate one or more of the above functions to an associate 
or sub-investigator.  However, the PI retains overall responsibility fo r proper conduct of the 
study, including obtaining and docum enting subject informed consen t, compliance with the study 
protocol, and the collection of all required data. 
 
Principal Investigator Statement: 
I the undersigned, have reviewed this protocol an d agree to conduct this st udy in adherence to the 
study protocol, GCP (Good Clinical  Practice) compliance, Ethical principles set forth in the 
declaration of Helsinki and authority regulations for the protection of human subjects 
participating in clinical trials. 
 
Print Name:  Signature:   Date: 
 
-----------------    ----------------- ------  ---------------  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 4 of 84 
 
 
 
Table of Contents 
 
1. Sponsor Statement of compliance .................................................................................. 2  
2. Investigator Ag reement: ................................................................................................. 3  
3. List of Abbr eviations ....................................................................................................... 7  
4. Protocol Sy nopsis ............................................................................................................ 9 
5. INTRODUCTI ON ............................................................................................................. 14  
6. BACKGROU ND ............................................................................................................... 14  
7. DEVICE NAME AND INTENDED USE ............................................................................... 17  
7.1 Device Na me ................................................................................................................. 1 7 
7.2 Intended Use ................................................................................................................ 1 7 
8. DEVICE DESC RIPTIO N .................................................................................................... 17  
8.1 Capsule ....................................................................................................................... .. 18  
8.1.1  Vibrant Ac tive: .............................................................................................................. 18 
8.1.2  Vibrant Plac ebo: ........................................................................................................... 19  
8.2 Accessory: activati on base unit ..................................................................................... 19  
8.3 Mode of op eration ........................................................................................................ 20  
9. RISKS & BENE FITS .......................................................................................................... 20  
9.1 Risks ......................................................................................................................... ..... 22  
9.2 Benefits ...................................................................................................................... ... 24  
10. ANIMAL INVESTIGATIONS  ......................................................................................... 24  
11. HUMAN CLINICAL INVESTIGATIONS  .................................................................. 25  
12. STUDY OBJE CTIVE ......................................................................................................... 33  
13. STUDY ENDP OINTS ........................................................................................................ 33  
13.1  Primary e ndpoint .......................................................................................................... 33  
13.2  Secondary e ndpoints  .................................................................................................... 34  
14. STUDY CONDUCT & POPULATI ON ................................................................................. 35  
14.1  Inclusion Cr iteria ........................................................................................................... 35 
14.2  Exclusion Cr iteria .......................................................................................................... 3 5 
14.3  Duration of  Study  .......................................................................................................... 36  
15. STUDY TREA TMENT ...................................................................................................... 37  
15.1  Study De sign ................................................................................................................. 37 
15.2  Medical Hi story ............................................................................................................. 3 9 
15.3  Constipation Histor y ..................................................................................................... 39  
15.4  Physical Exam inatio n .................................................................................................... 39  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 5 of 84 
 
 
 
15.5  Assessment of pelvic floor dysfunc tion (defecator y disorder) ...................................... 39  
15.6  Blood and urin e test s .................................................................................................... 40  
15.7  Screening visit (day  -21 to -14) ..................................................................................... 40  
15.8  Run-in period (day - 21 to -14, to -1) ............................................................................. 40  
15.9  Treatment .....................................................................................................................  41 
15.10  Rescue Trea tment ......................................................................................................... 42  
15.11  Termination visit ........................................................................................................... 4 3 
15.12  Concomitant me dication  .............................................................................................. 43  
15.13  Prohibited me dication .................................................................................................. 44  
15.14  Recording ..................................................................................................................... . 44 
15.15  Study Sche dule ............................................................................................................. 44  
15.16  Deviations from st udy protoc ol .................................................................................... 45  
15.17  Investigative Center Se lection Crit eria .......................................................................... 46  
16. ADVERSE EVENTS RECO RDING…………..  ....................................................................... ..46  
16.1  Reporting Requi rements ............................................................................................... 46  
16.2  Definiti ons ................................................................................................................... . 46 
16.3  Anticipated Adve rse Even ts .......................................................................................... 48  
16.4  Adverse Event Reporting .............................................................................................. 49  
16.4.1  Intensity or Severity  ...................................................................................................... 49  
16.4.2  Relatedness................................................................................................................... 49 
16.4.3  Outcome .......................................................................................................................  50 
16.4.4  Treatment or Ac tion ta ken ............................................................................................ 50  
16.5  Expedited Reporting of Se rious Adverse Events ........................................................... 50  
16.6  Follow- Up of Unre solved Ev ents .................................................................................. 51  
17. STATISTICAL CONS IDERATIO NS ..................................................................................... 51  
17.1  Study Design and Objectiv es ......................................................................................... 51  
17.2  Study Endpo ints ............................................................................................................ 52  
17.3  Statistical Hy pothesis  .................................................................................................... 52  
17.4  Sample size ...................................................................................................................  52 
17.5  Interim Anal yses ........................................................................................................... 52  
17.5.1      Procedure ......................................................................................................... ....... 52  
17.5.2  Blindi ng ...................................................................................................................... ... 52  
17.5.3  Decision Rules ............................................................................................................... 53 
17.5.4  Controlling the Alpha level for the primary endpoint ....... Error! Bookmark not defined.  
17.6  Randomizati on .............................................................................................................. 53  
17.7  Blindi ng ...................................................................................................................... ... 53  
17.8  Data Analysis  Sets  ......................................................................................................... 53  
17.8.1  Intent to Tr eat (ITT ) ...................................................................................................... 53  
17.8.2  Modified Intent to  Treat (m ITT) .................................................................................... 53  
17.8.3  Per-Protocol  (PP)  .......................................................................................................... 54  
17.8.4  Statistical Analysis of  Analysis Sets ............................................................................... 54  
17.9  Statistical Analysis ......................................................................................................... 54 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 6 of 84 
 
 
 
17.9.1  General Consid erations................................................................................................. 54  
17.9.2  Significance levels and hand ling of type I error ............................................................ 54  
17.9.2.1  Type I Er ror ............................................................................................................ 54  
17.9.3  Demographic and Other Baseline Vari ables .................................................................. 54  
17.9.4  Disposition of Subjects .................................................................................................. 55  
17.9.5  Efficacy An alysis ............................................................................................................ 55 
17.9.6  Treatment by Center  Interact ion .................................................................................. 55  
17.9.7  Safety An alysis .............................................................................................................. 56 
17.9.8  Handling of Missi ng Data  .............................................................................................. 56  
18. DATA MONITORI NG PLAN  ............................................................................................. 56  
19. DATA CONFIDEN TIALIT Y................................................................................................ 58  
20. FUNDING....................................................................................................................... 58 
21. ETHICS ........................................................................................................................ ... 58  
22. INFORMED CO NSENT .................................................................................................... 59  
23. REGULATORY AND HEALTH AUTHORITY AU DITS .......................................................... 60  
24. ELECTRONIC REPORT ING OF DA TA ............................................................................... 60  
25. RECORD RETE NTION ..................................................................................................... 60  
26. PROTOCOL MODI FICATION S ......................................................................................... 61  
27. PUBLICATION POLICY  .................................................................................................... 61  
28. SUBJECT / STUDY DI SCONTINUAT ION ........................................................................... 61  
29. DEVICE ACCOUN TABILITY  ............................................................................................. 62  
30. APPENDIC ES .................................................................................................................. 6 3 
31. REFERENCES .................................................................................................................. 6 3 
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 7 of 84 
 
 
 
3. List	of	Abbreviations 	
 
% Percent 
AE 
ADE 
AGA 
AR Adverse Event 
Adverse Device Effect 
American Gastroenterological Association 
Authorized Representative 
BMI 
BUN 
CSBM Body Mass Index 
Blood Urea Nitrogen 
Complete Spontaneous Bowel Movement 
eCRF 
CI Electronic Case Report Form 
Confidence Interval 
CIC Chronic Idiopathic Constipation 
DSMB Data and Safety Monitoring Committee 
EC Ethics Committee 
ECG 
EDC 
FA 
FC Electrocardiogram 
Electronic Data Capture 
Full Analysis Set 
Functional Constipation 
GCP Good Clinical Practice 
FDA Food and Drug Administration 
IBS-C ICF Irritable Bowel Syndrom e with Constipation 
Informed Consent Form  
ICH International Conference on Harmoni zation of Technica l Requirements for 
Registration of Pharmaceuticals for Human Use 
IFU Instruction for Use 
IRB 
ISF Institutional Review Board 
Investigator Site Files 
ITT Intent To Treat 
Mg Milligram 
g Microgram 
Min 
MFR 
NCAs 
NSAIDs minute(s) 
Manufacturer 
National Competent Authorities 
Non-Steroidal Anti-Inflammatory Drugs 
mITT Modified Intent to Treat OTC 
PAC-QOL 
PEG Over The Counter 
Patient Assessment of Constipation Quality of Life questionnaire 
Polyethylene glycol 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 8 of 84 
 
 
 
PI 
PP 
QOL Principal Investigator 
Per Protocol 
Quality of life 
SAE 
SADE 
SBM 
TSQM 
US USADE Serious Adverse Event 
Serious Adverse Device Effect 
Spontaneous Bowel Movement 
Treatment Satisfaction Qu estionnaire for Medication 
United States Unanticipated Serious Adverse Device Effect 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 9 of 84 
 
 
 
4. Protocol 	Synopsis 	
 
Title A prospective, multicenter, rando mized, single blind, Placebo-controlled 
study to assess the efficacy and safe ty of Vibrant capsule vs. Vibrant 
placebo for the Treatment of Chroni c Idiopathic Constipation (CIC). 
Indication The Vibrant Capsule is intended for the treatment of subjects with functional 
Constipation. 
Objectives The objectives are to assess the ef ficacy and safety of the Vibrant capsule 
administered 5 times per week  
Number of 
Subjects up 60 pts 
 
Number of 
centers The study will be performed in up to 20 centers in the USA. 
Study 
Duration Study duration is 10 to 11 weeks 
- 2 to 3 weeks of run-in 
- 8 weeks of treatment  
Design The study is a prospective, multi center, randomized, si ngle blind, placebo-
controlled study, to evaluate the efficacy  and safety of the Vibrant Capsule 
vs. Vibrant placebo in relieving constip ation in subjects with functional 
constipation. 
 
Two arms will be assessed:  
- Vibrant Capsule administered 5 times per week 
- Vibrant Placebo Capsule admin istered 5 times per week 
 
An interim analysis will be performed after all the subjects h ave completed  
4 weeks of  treatment. The following parameters will be assessed: main 
safety parameters, and a p ecific efficacy parameter.  
 Depending on the results of  the interim analyis: 
 The study will be stopped, 
 The study will continue as planned. 
 
Method   
Subjects  will come for 4 visits: Screening (v isit 1), baseline (visit 2), after 4 
treatment weeks (visit 3), after 4 treatme nt weeks Final visit (visit 4). A total 
of 8 treatment weeks. 
 
Visit 1 -Screening: Subjects will be screened to the study at the screening 
visit, PAC-QOL questionnaire will be completed and subject will have a 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 10 of 84 
 
 
 
run-in time for a period of 2-3 week s, assuring 14 consecutive days of 
eDiary with an average of < 3 SBM per week . 
 
Visit 2 - Baseline: After the run-in period, the subjects will return and 
eligibility will be re-asse ssed. Subjects will be randomized to either Vibrant 
or Vibrant placebo for a treatment period of 8 weeks. Subjects, in both arms, 
will have their first administration of  Vibrant capsule / Vibrant placebo on 
site at the day of baseli ne visit and will be inst ructed on their treatment 
administration at home and will be reque sted to ingest the capsules at a 
specific time of the day. At baseline, s ubjects will also be trained on how to 
use the base unit at home.  
  
Subjects will be instructed to comple te a simple subject eDiary each day 
throughout the duration of the study (including the run-in period).  
The eDiary will include questions on: 
 Daily BM, SBM, CSBM  
 Change of their diet, if applicab le (NOTE: the protocol will not 
ask/require the subjects to cha nge anything in his/her diet)  
 Change in sympotms as: brisol st ool consistancy, straining, bloating, 
and the other questions in the eDiary    
 Medication 
 AE (including diarhrea) 
 The first 2 weeks of treatment will be  considered as a subjects’ training 
period. 
Visit 3 –after 4 weeks of treatment  - an on site visit will take place to 
evaluate subject's safety and treatment efficacy  and additional capsule 
dispencing .  
Visit 4 Final visit –after a nother 4  weeks of treatment  - an on site visit will 
take place to evaluate subject's safety and treatment effic acy and collect the 
base unites and remaning capsules.  PAC-QOL, Ease of use and TSQM 
questionnaires will be completed. 
During the entire study period, data reporti ng will be done on an electronic 
Case Report Form (eCRF) and an eDiary. 
Subjects will be asked to refrain fro m taking any medica tion or supplement 
to relieve their cons tipation, during the en tire study period.  
Subjects will receive phone calls at least once a week and subject 
compliance will be monitored  thro ughout the 8 weeks of the study. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 11 of 84 
 
 
 
Subjects will be authorized to use rescue medication after 3 consecutive 
days without a bowel movement.  
Data about time of activation of the cap sules will be automatically registered 
and transmitted by the base unit  for Vibrant capsules.  
 
Endpoints Primary endpoints  
Efficacy:  
The primary efficacy endpoint is CSBM success rate, defined as an increase 
from the run-in period of at least one  weekly Complete Spontaneous Bowel 
Movement (CSBM) during at least 6 of the 8 weeks  of treatment. 
CSBM & SBM is defined as a bowel move ment that occurs at least 48h after 
laxative/rescue intake wi thout digital maneuver) 
• Subjects with less than 2 weeks (with  at least 5 days per week) of 
valid diary entries during the treatme nt period will be considered as 
non-evaluable.  
  
Safety Endpoints: 
• Safety endpoints includ e all adverse events related and unrelated to 
the study treatment 
 
 
Secondary efficacy endpoints include:  
• SBM success rate, defined as an increase from the run-in period of at 
least one weekly Spontaneous Bo wel Movement (SBM) during at 
least 6 of the  8 weeks of treatment. 
• Change from baseline in average st ool consistency, using the Bristol 
Stool Scale 
• Change from baseline in average straining. 
• PAC-QoL 
 
 
Additional effic acy endpoints  
• Change from baseline in  average bloating. 
• Number / percentage of subjects who reported using rescue 
medication during treatment period  
• Change from baseline in weekly  number of Spontaneous Bowel 
Movement (SBM). 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 12 of 84 
 
 
 
• Change from baseline in weekly number of Complete Spontaneous 
Bowel Movement (CSBM). 
• Rate of SBM ≤ 24 hours after first dose 
• Change from baseline in average abdominal gas. 
• Change from baseline in average abdominal pain. 
• Change from baseline in abdominal discomfort. 
• Time to occurrence of spontane ous bowel movement after first 
capsule activation. 
• Ease of use  
• TSQM (validated treatment satisfaction questionnaire)   
Subject 
Population Subjects with Functional Constipation refractory to existing treatments.  
Inclusion 
criteria 1. Subjects aged 22 years and older 
2. Subjects with Chronic Idiopathic Constipation (CIC) according to 
Rome III criteria and who have not experienced relief of their 
symptoms from available therapies (osmotic and stimulant laxatives 
used for at least one mo nth at recommended dose) 
3. Subjects with an average of <3  Spontaneous Bowel Movements 
(SBM) per week  
4. Normal colonoscopy performed wi thin 5 years prior to study 
participation, unless th e subjects are <50 years old and without alarm 
signs and/or symptoms 
5. Subject signed the Inform ed Consent Form (ICF) 
6. Female subjects must have a nega tive blood pregnancy test during 
screening, confirmed by a negati ve urine pregnancy test during 
baseline and must not be l actating prior to receiving study 
medication. For females of child-be aring potential, a hormonal (i.e., 
oral, implantable, or injectable ) and single-barr ier method, or a 
double-barrier method of birth contro l must be used throughout the 
study. All other female subjects mu st have the reason for their 
inability to bear children documen ted in the medical record [i.e., 
tubal ligation, hysterectomy, or post-menopausal (defined as a 
minimum of one year since the la st menstrual period)]; in these 
circumstances, a pregnancy te st will not be necessary.  
 
Exclusion 
criteria 1. History of complicated/obstr uctive diverticular disease 
2. History of intestinal or colonic obstruction, or suspected intestinal 
obstruction. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 13 of 84 
 
 
 
3. History of significant ga strointestinal disorder , including any form of 
inflammatory bowel disease or ga strointestinal malignancy (celiac 
disease is accepted if th e subject has been treated  and is in remission) 
4. History of gastroparesis 
5. Use of any of the following medications:  
o Medications that may affect intestinal motility, prokinetics, 
anti-Parkinsonian medications , opiates, opioids, calcium-
channel blockers, alumin um/magnesium hydroxide 
o With the exception of antidepressants, thyroid or hormonal 
replacement therapy, when the subject has been on a stable 
dose for at least 3 months  prior to enrollment. 
6. Clinical evidence of significant re spiratory, cardiovascular, renal, 
hepatic, biliary, endocrine, psychi atric or neurologic disease. 
7. Presence of cardiac pacemaker or gastric electrical stimulator. 
8. History of, or current ea ting disorders, such as  anorexia, bulimia, or 
compulsory overeating. 
9. Diagnosis of mega-rectum or  colon, congenital anorectal 
malformation, clinically significant re ctocele, history of intestinal 
resection (with an exception for appendectomy, cholecystectomy and 
inguinal hernia repair), history of bariatric surgery or evidence of any 
structural abnormality of the gastrointestinal tract that might affect 
transit 
10. History of Zenker’s diverticulum , dysphagia, Barrett's esophagus, 
esophageal stricture or achalasia 
11. Chronic use of non-steroidal anti -inflammatory drugs (NSAIDs): 
chronic use is defined as taking full dose NSAIDs more than three 
times a week for at least six m onths. Subjects on cardiac doses of 
aspirin may be enrolled in the study  
12. Subjects with pelvic floor dysfunc tion/defecatory disorder, based on 
subject history 
13. Participation in another clinical  study within one month prior to 
screening. 
14. Women who are pregna nt or lactating 
15. Use of any medication for constipat ion relief during the study, except 
as rescue medication, as  indicated by study rules 
16. Inability to use an electronic daily Diary (on a computer, phone 
application, tablet or other el ectronic device) to report bowel 
movements, symptoms and medication usage 
17. Subject participated in a previous Vibrant study 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 14 of 84 
 
 
 
18. Any other condition which in the opinion of the investigator may 
adversely affect the safety of the subject or would limit the subject's 
ability to comp lete the study 
Statistical 
analysis  
Sample size: 
No formal sample size calculations were performed. A sample size of 40 subjects (20 in each arm) is deemed sufficient to fu lfill the main goals of 
the study. The sample size may be increased to up to 44 s ubjects to account for a 
potential ~10% drop-out rate.  Main Efficacy Analysis: Statistical analyses will be mainly descriptive in nature. The subject’s 
CSBM success status (i.e. if the subject s achieve an increase from baseline 
of at least 1 weekly CSBM during at least 6 of the 8 treatment weeks) will 
be presented in tabular form by stud y arm, along with 95% Wilson score 
Confidence Intervals (CI).  
	
 
5. INTRODUCTION 	
 
This document is a clinical re search protocol and the descri bed study will be conducted in 
compliance with the protocol, standards of Good Clinical Practices and associated regulations, 
and all applicable research requirements. 
6. BACKGROUND 	
 
Chronic constipation is a common gastrointestinal di sorder in the gene ral population. It is 
estimated that chronic constipa tion affects between 2 and 27% of the population. A majority of 
chronic constipation su fferers are women, who represent three-fourths of those affected1. 
Constipation may be primary (Chronic Idiopathic  Constipation (CIC), Irritable Bowel Syndrome 
with Constipation (IBS-C)) or secondary to other factors (such as drugs like opioids, colorectal 
cancer, diabetes, Parkinson’s disease or spinal cord injury). It is estimated that 100 million adults 
in the United States (US) have chronic pain2.  
There is no widely accepted definition of chroni c constipation. Although physicians often define 
constipation based on stool frequ ency, subjects expe rience constipation as a multi-symptom 
disorder that includes infrequent bowel movement s, hard or lumpy stools, straining, bloating, a 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 15 of 84 
 
 
 
feeling of incomplete evacu ation after a bowel movement  and abdominal discomfort3. The Rome 
Foundation has created symptom-based diagnostic cr iteria for chronic cons tipation. To meet the 
definition of chronic constipation, the criteria must be  fulfilled for the prior 3 months with 
symptom onset at least 6 months prior to diagnosis4.  
Chronic constipation impacts quality  of life and is perceived by subjects as a severe disease3.  
Adding to the burden of disease,  constipation is among the ten mo st expensive gastrointestinal 
diseases in terms of direct and indirect healthcare costs5. A recent systematic review of the 
disease burden of IBS and CIC found the attributable direct costs of IBS to range from 
approximately $1,600 to $7,500 per subj ect-year, whereas the attribut able direct costs of CIC 
range from approximately $1,900 to $7,500 per subject-year6. 
Although a variety of treatment op tions are available for chroni c constipation, subjects have 
reported low satisfaction with current treatment al ternatives in multiple published studies.  Thus, 
there is a need for additional therapeutic options that address subject symptoms and preferences. 
Constipation Management  
The American Gastroenterological  Association (AGA) has establ ished a treatment  algorithm for 
constipation that provides multiple therapeutic steps depending on severity of symptoms.  See 
http://www.gastrojournal.or g/article/S0016-5085(12)01545-4/pdf . The first step in the treatment 
of constipation focuses on  lifestyle modification  with three main parameters: adequate fluid 
intake, a high fiber diet a nd regular physical activity. 
Fiber absorbs water, increases stool bulk, and in doing so stimulates the bowel to decrease stool 
transit time and ease evacuation.  Medicinal and dietary fiber suppl ements, such as psyllium, can 
be added to the high fiber diet or used as primary therapy. 
If lifestyle modification does not produce satisfactor y results, subjects ha ve access to a number of 
FDA-approved products (Food and Drug Administrati on), available both ov er the counter (OTC) 
and by prescription. Stool softeners (docusate sodium, docusate calciu m) act by decreasing 
surface tension to allow water to enter the bow el more readily, making the stool softer, which 
makes it easier and less painful to  pass. However, there is curren tly limited data on the efficacy 
of stool softeners in s ubjects with constipation1.  
Osmotic laxatives are also available, including po lyethylene glycol (PEG),  lactulose, magnesium 
hydroxide, magnesium citrate, ma gnesium sulfate, and sodium phosphate. PEG and lactulose 
have been shown to improve stoo l frequency and stool consistency1,6,7.   
Osmotic laxatives contain poorly absorbed ions or molecules that retain wa ter in the intestinal 
lumen. Although effective, they can cause bloa ting and cramping.  In addition, due to their 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 16 of 84 
 
 
 
mechanism of action, they should be used with caution in older adults and in subjects with renal 
impairment because of the risk of de hydration and electrolyte disturbances. 
Stimulant laxatives include senna, bisacodyl or  sodium picosulphate. They induce fluid and 
electrolyte secretion by the col on or induce peristalsis in the colon, thereby producing a bowel 
movement.  
Recent advances in research have resulted in new classes of medicati on for the treatment of 
constipation, available on prescription. For example, linaclotide is an agonist of guanylate 
cyclase-C receptors, and increases chloride, bicarbonate and fluid secretion into the intestinal 
lumen, lubricating the stool and accelerating gastrointestinal transit. Linaclotide was FDA-
approved in 2012 for CIC and IBS-C. Adverse events include diarrhea, which leads to 
discontinuation of the medication in  approximately 5% of subjects8.  In total, 8% of subjects in 
linaclotide clinical trials disc ontinued due to adverse events, a nd 27% had their dose reduced or 
suspended secondary to adverse reactions, the majority of which were diarrhea or other 
gastrointestinal adverse reactions.  See http://www.accessdata.fda.gov/drugsatfda_docs/label/ 
2014/202811s004lbl.pdf  
 
Lubiprostone is approved for use in women with  IBS-C and in men and women with CIC, as well 
as opioid-induced constipation in subjects with non-cancer pain. It is a selective chloride channel 
activator, increasing i on and fluid secretion. The main ad verse events associated with 
lubiprostone are mild to moderate nausea and diarrhea2,9.  Approximately 29% of subjects who 
received lubiprostone 24 mcg twice daily in clini cal trials experienced nausea; 4% of subjects had 
severe nausea while 9% of subj ects discontinued treatment due to  nausea. Approximately 12% of 
subjects who received lubipros tone 24 mcg twice daily experien ced diarrhea; 2% had severe 
diarrhea while 2% discontinued trea tment due to diarrhea.  In a ddition, it has been reported to 
cause dyspnea, which was reported in 2.5% of the treated chronic id iopathic constipation 
population and 0.4% in the treate d IBS-C population. Although not cl assified as serious adverse 
events, some subjects discontinued treatment becau se of this event. These events have usually 
been described as a sensation of chest tightness and difficulty taking in  a breath, and generally 
have an acute onset within 30- 60 minutes after taking the first dose. They generally resolve 
within a few hours after taking the dose, but recurrence has be en frequently reported with 
subsequent doses.  See http://www.accessdata.fda.gov/ drugsatfda_docs/label/ 
2008/021908s005lbl.pdf .   
In subjects with severe chroni c constipation, surgery may be considered; how ever, it is generally 
limited to use in the most severe cases after medi cal management has failed to provide adequate 
relief.  In subjects with severe  incapacitating slow transit constip ation, colectomy with ileorectal 
anastomosis can improve constipation and related symptoms10,11. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 17 of 84 
 
 
 
In summary, while there are a va riety of treatments av ailable for constipation, there is currently 
no satisfactory treatment for many constipated subjects:  a US study showed that 47% of 
constipated subjects are not completely satisfi ed with their current constipation treatment3, while 
a European study showed that only 27% of European  subjects are satisfied with current treatment 
options5. Furthermore, many subjects become refractory to one or more OTC laxatives with 
chronic use, which may cause frustration for both the clinician and the subject, and ultimately 
leads many subjects to abandon therapy and remain dissatisfied with their condition2. Nearly 90% 
of subjects express inte rest in new therapies12.  
 
7. DEVICE	NAME	AND	INTENDED 	USE	
7.1 Device Name  
 
Vibrant Capsule 
 
7.2 Intended Use  
The Vibrant Capsule is an orally administered non-biodegradable vibrat ing capsule intended to 
be prescribed for the treatment of adult chronic idiopa thic constipation in patients who have not 
experienced relief of their symp toms from available therapies (osmotic and stimulant laxatives 
used for at least 1 month at recommended dosage).  
8. DEVICE	DESCRIPTION 	
The Vibrant Capsule is designed to  mechanically induce a peristaltic wave in the large intestine, 
thus aiding in relieving constipated subjects. Constipation relief is ac hieved by the capsule’s 
vibrations impinging on the gastro intestinal wall, consequently i nducing peristaltic activity which 
promotes transit and facilitates defecation. 
 
The Vibrant Capsule has se veral important features: 
 Small Dimensions. 
 Easy to swallow (smooth shell). 
 Delay Mechanism - A delay mechanism was incorporated in this device to allow 
sufficient time for the capsule to arrive at the large intestine before it starts vibrating. The 
delay mechanism is the time between swallo wing the capsule and act ivation and inducing 
vibrations within the large intestine. This is obtained by a software programing 
mechanism. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 18 of 84 
 
 
 
 Sequence Mechanism – sequence of vibration, specifically adapted for subjects with 
constipation. 
The capsule is activated by an el ectromagnetic signal which carries  an Activation Code using the 
activation base unit prior to swallowing the capsule.  
 
8.1 Capsule 
8.1.1 Vibrant Active:  
The Vibrant non-biodegradable capsule is compri sed of a flat motor,  electronic card and 
batteries, all encapsulated in a 2-piece shell (p lease refer to Figure 1 below). The capsule is 
activated by an electromagnetic signal which ca rries the Activation Code using the activation 
base unit, prior to swa llowing the capsule.    
 
 
 
 
  
 
 
 
 
 
 
The capsule dimensions are: 
 Length : 24.2 ± 0.1 mm 
 Diameter : 11.3± 0.1 mm 
 
The capsule shell is made of a well-know n biocompatible material: PC MAKROLON 2458. 
Shell is hard & non-biodegradable  
Before starting the vibrating action and to ensure the capsule has arri ved at the large intestine, the 
company has integrated a tightly controlled vibr ating algorithm that will define number of hours 
from the activation to the vi brating phase (delay time). 
This delay will allow the capsule to reach the large intestine before starting the vibrations. 
  
 
 
The capsules are packaged in a bliste r of 10 units (cf. Fig. 2 below).  Figure 1. The capsule and components  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 19 of 84 
 
 
 
 
 
8.1.2 Vibrant Placebo:  
A biodegradable capsule, which visually similar to the Vibrant active capsule. 
 
8.2 Accessory: activation base unit 
 
A user friendly activation base was de veloped by the company for subject use 
(please refer to Fig 3 below). The activation base (or base unit) is meant to be used at home by 
subjects. The base unit is easy to use and re quires a simple training before taking it home. 
Subjects will activate the capsu le themselves at home.  
 
 
The activation base is composed of: 
  An electronic circuit board  
  Electromagnetic antenna bedding the capsule.  
 
 
1. Base Unit 
2. USB cable  
3. AC/DC USB adapter  
 
 
 
 
 
 
 
 
 
1. Base Unit Cover 
2. The "Ready" Green Light Indicator 
3. The Designated Groove for Capsule 
4. The "X" Red Light Indicator 
5. The "ON" Green Light Indicator 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 20 of 84 
 
 
 
 
 
Figure 2. Activation base: desc ription of components and image 
 
Setting up the base unit 
First, the user connects the base unit to an el ectricity outlet, with the USB cable and AC/DC 
adapter. The green “ON” light on the base unit turns on and a short “buz z” is heard, indicating 
that the base unit is  ready for use.  
 
Activation of the Vibrant Capsule using the base unit 
 
 
 
8.3 Mode of operation 
The Activation base is shipped in a pr otective package containing the following: 
- Base Unit 
- USB cable  
- AC/DC USB adapter  
- Instructions for use  
The Vibrant Capsules are shipped in  a blister containing 10 capsules. 
 
Capsule activation: 
1. The capsule will be placed in the designated groove in the center 
2. The green "Ready" indicator light turns on 
3. The capsule is ready to be administered by the subject. 
4. Capsule will reach the large intestine (w ithin approximately 6-8 hours) and start 
predefined vibrating program, inducing peristaltic activity.  
5. Capsule will be extracted from the body during normal bowel movement. 
 
Additional details can be found within the Inve stigator's Brochure (Document # 114CLD,) and 
the Instruction For Use (IFU) for the vibrating capsule (Document # 117LAB). 
 
9. RISKS	&	BENEFITS 	
 
The Vibrant Capsule is designed according to international standards for medical devices. 
Compliance with these standards ensures that the device can be used safe ly in human beings.  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 21 of 84 
 
 
 
Biocompatible materials are used for the vibrating capsule compone nts. The use of biocompatible 
materials should protect the subject of a ny hazardous from possibl e adverse events.  
 
The device classification according to ISO10993-1 and FDA’s guidance Use of International 
Standard ISO-10993-1:2009, "Biological Evaluation of  Medical Devices Part 1: Evaluation and 
Testing" :  Draft Guidance for Indust ry and Food and Drug Administration Staff (“FDA 
Biocompatibility Guidance”) is as follows:  
Category:  Surface device. 
Contact duration: perman ent contact (>30 days) 
Contact:  breached or compromised surfaces. 
 
According to this classification, the following tests were performed, all of which had passing 
results: Cytotoxicity Study Using the ISO El ution Method, Bacterial Reverse Mutation Study, 
ISO Intracutaneous Study in Rabbits, ISO Syst emic Toxicity Study in Mice, ISO Guinea Pig 
Maximization Sensitization Test, Mouse Peri pheral Blood Micronucleus Study, Genotoxicity: 
Mouse Lymphoma Assay, ISO 10993-18 - Chemical Characterization 
 
A biological risk assessment  of the Vibrant Capsule has al so been performed by NAMSA in 
accordance with ISO 10993-1:2009 requirements. The purpo se of this study is to use information 
from biological safety studies of the materials used to manufacture the Vibrant Capsule, chemical 
characterization data, and biologi cal safety test results on the device to support and demonstrate 
the overall biological safety of th e Vibrant Capsule. This assessment focuses on the requirements 
of ISO 10993-1:2009, EN ISO 14971:2012, FDA Ge neral Program Memorandum #G95-1 and 
the 2013 Draft Biocompatibility Guidance, and th e European Union Medical Device Directive 
93/42/EEC. 
 
The company also evaluated the mechanical, struct ural integrity, electrical safety, shelf life and 
other characteristics of the Vi brant Capsule when subjected to clinical use conditions.  
 
Testing performed incl uded the following:  
a. Visual inspection 
b. Dimensional verification of the capsule 
c. System delay mechanis m verification test 
d. pH Resistance test 
e. Mechanical integrity test  
f. Evaluation of capsules Vibrations sequence 
g. Electrical safety and EMC  
h. Environmental and tr ansportation test. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 22 of 84 
 
 
 
   
9.1 Risks 
 
The Vibrant capsule has been designed to mechan ically induce a normal peristaltic wave in the 
large intestine, thus aiding in relieving constipat ed subjects.  
 
The capsule moves through the ga strointestinal system, without interacting with any other body 
system and does not deliver medication of any kind. The Vi brant capsule targets basic 
pathophysiological factors contribu ting to chronic constipation by inducing intrinsic contractile 
activity without using chemical  supplements. The capsule op erates without any biological 
interference. 
 
The capsule has been sealed up by using a biocom patible shell and will remain sealed up until it 
has been excreted out of the human body, thus en suring that, as it transits  the gastrointestinal 
tract, there will be no unwanted outputs of energy or substance. This has been evaluated and 
confirmed in preclinical test ing (please refer to the st udy investigational brochure). 
 
The capsule coating (a biocompa tible and widely used shell) protects the s ubject from any 
potential hazards that might be associated with its contents. The energy of the batteries is 
harmless and cannot leak while the capsule remain s intact (break force was tested up to 60 
Kgf/cm²). The capsule was test ed for Safety and EMC 60601 tria ls. No ionizing radiation is 
emitted and no thermal energy generated. 
 
Device manufacturing and assembly is done in an ISO 13485:2003 facility. 
 
 
 
Adverse events 
Potential adverse events associated with the use of this device may include abdominal pain, blood 
in stool and diarrhea. In rare  cases obstruction may occur  
 
Warnings: 
 The Vibrant Capsule has not been evaluated for safety and compat ibility in the MR 
(magnetic resonance) environmen t. It has not been tested for heating, migration, or image 
artifact in the MR (magnetic resonance) envi ronment. The safety of the Vibrant Capsule 
in the MR (magnetic resonance) envir onment is unknown. Scanning a patient who has 
this device may result in patient injury  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 23 of 84 
 
 
 
 A thorough understanding of the technical prin ciples, clinical app lications and risks 
associated with the Vibrant capsules is  necessary before using this product 
 If you have reasonable doubt concerning the inte grity of a Vibrant capsule, it should not 
be used and discarded 
 A Vibrant capsule should not be in gested after its expiration date 
 Avoid biting the Vibrant capsule prior to swallowing 
 After ingesting a Vibrant capsule and until it is excreted, you should not be near any 
source of powerful electromagnetic fields su ch as one created near an MRI device 
 The capsule should be kept aw ay from implants such as pace makers, defibrillators, nerve 
stimulators, and other devices that could be af fected by proximity to a DC (direct current) 
magnetic field 
 If after ingesting a Vibrant cap sule you experience any abnor mal abdominal pain, nausea 
or vomiting, you should contac t a physician immediately  
 Vibrant capsules must be stored in a safe place,  out of the reach of children and/or infants  
 If a child has accidentally swallowed an unused Vibrant capsule, he/she should be brought 
immediately to a hospital  
 The Vibrant capsule is adminis tered by prescription only and should not be given to 
anyone without a prescription  
 Undergoing an MRI while the capsule is inside  your body may result in serious damage to 
your intestinal tract or abdominal cavity. If you require an MRI instruct your physician to 
verify capsule expulsion via abdominal X-ray before undergoing an MRI examination  
 The safety of this device has not been es tablished in pregnancy and/or lactation  
 The safety of this device in patients with signi ficant gastrointestinal diverticular disease is 
unknown  
 The safety of this device has not been established in adolescents  
 
Safety in Animal and Human Clinical Investigations 
 
No safety concern was raised during an imal and human clinical investigations. 
 
The animal studies and human inve stigation studies demonstrated  safety of the capsule to 
support subsequent studies in the target popul ation. All capsules were  extracted safely 
with no related serious adverse events and all clinical and la boratory results were within 
normal values. For more details see section 11: Human Clinical Investigations. 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 24 of 84 
 
 
 
9.2 Benefits 
 
 
Human Clinical Investigations 
 
Phase 1, 2a and 3 studies showed clinical benefits with the Vibrant Capsule: the capsule increased the 
number of weekly SBM / CSBM among subjects with constipation and improved constipation symptoms, 
such as straining, bloating and stool consistency. For more details see section 11: Human Clinical 
Investigations. 
 
 
10. ANIMAL	INVESTIGATIONS 	
 
Two animal studies were conducte d using the Vibrant Capsule: 
The initial study was approved by Helsinki comm ittee for animal studies (approval no. IL-089-
09-2008), and performed at the Technion – Isr ael Institute of Technology. The study was 
overseen by the committee for the supervision of animal experiments. Study objectives were to 
evaluate the safety and physiologi cal effect of the vibrating caps ule in 3 dogs. On study initiation 
the dogs were given sham capsules to evaluate de fecation time, clear passa ge of the capsule and 
safety. After approximately 1 week each animal  swallowed a vibrating capsule in different 
intervals starting from 3 da ys to two week interval s during a 6-month period. 
 
Final analysis showed that the capsules were sa fe for use – they were not damaged even when 
bitten by the dogs. There was no evidence of any discomfort or advers e effects on the dog’s 
health. Evidence of effectiveness of the capsule  was indicated by reduced  defecation time with 
the vibrating capsule compared to  the Sham, without creating artifi cial constipation conditions in 
the dog's gastrointe stinal tract.  
 
The second study was conducted at the Rambam Hospital in Haifa, Israel.  The study was 
approved by the Helsinki committee for anim al trials (approva l no. IL-130-11-2009).  
Study objectives were to evaluate the safety and physiological effe ct of vibrating capsule in 2 
dogs. On study initiation the dogs were given sham  capsules to evaluate defection time, clear 
passage of the capsule and safety. After approxim ately 2 days each animal ingested a vibrating 
capsule every second day for two weeks' time and was followed for an additional month. Capsule 
delay time was adjusted for the animal model (8 hours for a smaller dog  and 16 hours for a bigger 
dog). Clinical observations were recorded by lab personnel to ensure no signs of distress, pain, 
vomiting or irregular behavior. In addition X-ray was used to  verify capsule location and 
vibrating movement. The time of  defecation and stool consistenc y were recorded. The capsules 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 25 of 84 
 
 
 
were retrieved from the dog stools.  Capsule integrity wa s confirmed; capsule s were whole with 
no defects in seal, no ruptures, no sh ell cracks or any other damage.   
 
In all the animals the capsule were passed by the dogs wit hout any adverse effects to the dog 
and/or any damage to the capsules. There was no evidence that the capsule's colon transit or its 
vibration caused any adverse e ffect to the dog's physical health  and behavior.  Evidence of 
effectiveness of the capsule was indicated by redu ced defecation time with the vibrating capsule 
compared to the Sham. Moreover, one dog suffere d from constipati on for 4 days (not induced by 
the study), which was relieve d by the vibrating capsule.  
 
11. HUMAN CLINICAL INVESTIGATIONS 
 
Vibrant Ltd. has completed  five human clinical investigations.  
 
Total Exposure – Human Clinical Investigations 
The human clinical investigati ons performed by Vibrant exposed a total of 449  participants, 
healthy or constipated, to either the Vibrant Capsule or the Sham Capsule. 
In total, 259 subjects received the Vibrant Capsule.   
 
The remaining 190 subjects who participated in clinical investigations  received the Sham 
Capsule. 
 
Phase 1 clinical investig ation – healthy volunteers 
 
An initial clinical study was a pproved and initiated in 2 sites in Israel (Tel-Aviv Sourasky 
Medical Center and The Holy Family Ho spital, Nazareth), from March 8 to 24th, 2011. The study 
was initially approved for use in 6 healthy volunt eers in order to evaluate the safety of the 
Vibrant Capsule in a prospectiv e, open-label, single group study. 
Six consecutive healthy volunteers  (3 men and 3 women) ages 21 to 41 years, all fulfilling the 
exclusion/exclusion criter ia, were enrolled in the study. During  the Baseline study visit, subjects 
were evaluated for eligibility and went through physical examin ation, vital sign measurements, 
ECG measurements and blood tests,  which were all within the nor mal values. Eligible subjects 
were asked to take 1 vibrating capsule by the st udy personnel.  Subjects were followed for 7 days 
on their normal bowel movements a nd excretion of the capsule.  One week following the baseline 
visit, subjects returned for a visit and repeated the physical ex amination, vital si gn measurements, 
ECG measurements and blood tests.  
All capsules were evacuated from  the body, along with stool, safely with no adverse events. 
Average time for capsule excretion was 2.2 days (2 days for 4 subjects, 1 day for 1 subject, and 6 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 26 of 84 
 
 
 
days for 1 subject). All clinical and laboratory results were within normal values.  Thus, this 
preliminary study demonstrated safety of the capsule  to support subsequent studies in the target 
population. 
 
Phase 2a clinical investigation   
V-111: "A Prospective, open-label, sa fety evaluation of the Vibratin g capsule in ai ding reliving 
constipated individuals" 
The study was conducted in the Departments of Ga stroenterology and Hepatology at the Tel-Aviv 
Sourasky Medical Center and at  The Nazareth Holy Family Hospital, beginning in July 2011.  
Study design: Prospective, Open Label, Si ngle Group Assignment, Safety pilot Study.  
Objective: safety  
Study population: 26 Subjects with Chronic Cons tipation or Irritable Bowel Syndrome With 
Constipation 
Endpoints: The primary endpoint  was safety, assessed descri ptively by summa rizing adverse 
events (AEs), clinical laborator y test results, vital sign measur ements, and ECG measurements.  
The secondary endpoint was efficacy, determined as an increase of more than one spontaneous 
bowel movement (SBM)/week durin g the 7.5 weeks of treatment compared to the 2-week run-in 
period.  The number of spontane ous bowel movements was calcul ated as a weekly average. 
Methods: 2 capsules/ week for 8 weeks of treatment 
Each capsule was collected from the stool by subject , before the next capsule was administrated.  
Results: Safety - 15 AEs were observed during the study for 8 subjects (36.4%  of the subjects), 
none of them was serious. 8 AEs were possibly related to study devi ce for 5 subjects (22.7% of the 
subjects) 
Efficacy - Mean increase of SBM =1.78, Std=1.09, p<0.001 
Conclusion: The Vibrant capsu le found to be safe.  
 
The next study was conducted to eval uate safety and efficacy (V-179) 
 
 
 
Comparative clinical investigation   
V-179: "A multinational, multicenter, prospect ive double-blind, sham controlled, randomized 
study to assess the performance, ef ficacy and safety of Vibrating Capsule medical device in aiding 
relieving Constipated Individuals " 
 
The study was conducted in 16 sites (10 in the US A and 6 in Israel) from Aug 2014 until Jan 2016. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 27 of 84 
 
 
 
Study design: The study was a multinational, mu lticenter, prospective, randomized, double-blind, 
sham controlled trial. Identical capsules were used in the sham arm, elimin ating only the activation 
of the capsule in the large in testine, for the sham group.  
Study objectives: The purpose of the investigation was to evaluate the efficacy and safety of the 
Vibrant Capsule compared to a sham non-vibrat ing capsule on spontaneous bowel movements 
Study population: 154 (77 in each group)  Subjects with Chronic Idi opathic Constipation according 
to Rome III criteria who failed currently available therapy (osmot ic and stimulant laxatives which 
was used for at least one month at recommended dose).  
 
Endpoints: the primary endpoints were safety and efficacy.  
Safety: related AE's/SAE's 
Efficacy: an increase of at least 1 weekly SBM from baseline in at least 6 (of 8) weeks 
during the treatment period and improvement  of at least 1 point in PAC-QOL from 
baseline.  
 
The secondary endpoints were:  
1. Change from baseline in weekly SBM 
2. Time from fist Vibrant pill intake (either active or sham) to first SBM 
3. Number of rescue therapy uses  during the treatment period 
4. Change from baseline in PAQ-QOL score 
5. Change from baseline in stool consistency as  classified with the Bristol stool chart 
 
Methods: 2 capsules/ week for 8 weeks of treatment 
Results: A total of 252 Adverse Events (AE’s) were reported in the active ar m and 183 in the sham 
arm. 2 AE’s were considered serious: 1 in the ac tive arm - a fractured nose considered not related 
and 1 in the sham arm - a viral syndrome considered not related 
 
A summary of adverse events severity is provided below.  
 
 
 
  
  Vibrant Group Sham Group 
Number 
of reports Number of 
subjects IncidenceŦ Number of 
reports Number of 
subjects IncidenceŦ 
Any Adverse Event 252 51 62.20% 183 44 54.32% 
Mild 203 42 51.22% 136 34 41.98% 
Moderate 47 21 25.61% 44 18 22.22% 
Severe 1 1 1.22% 1 1 1.23% 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 28 of 84 
 
 
 
Adverse Event Leading 
to Discontinuation 0 0 0% 0 0 0% 
Ŧ The incidence is defined as the percent of subject’s report ing a specific AE at least once,  out of the total number of 
subjects in that group.  
 
The primary efficacy endpoints results are:  
1. SBM: 45.45% vs. 46.75% in Vibrant a nd Sham respectively (p= 0.8552).  
2. In a sub-group analysis  50% of the population (N=77) (Pts  who have avg of 1-2.5 SBM at 
baseline): SBM: 59.5% vs. 47.5%  in Vibrant and Sham resp ectively (p=0.2933). CSBM: 35.1% 
vs. 15.0% in Vibrant and Sham respectively (p=0.0406) 
3. Improvement of QOL from baselin e: 26.1% vs. 32.0% in Vibrant and Sham respectively (p= 
0.4409) 
 
The secondary endpoints results are: 
1. Change from baseline in stool cons istency: Average change from ba seline in Bristol score: 0.9 
vs. 0.6 Vibrant and Sham respectively (p=0.1303)  Sub-group analysis - Average change from 
baseline in Bristol scor e: 1.1 vs 0.6 Vibrant and Sh am respectively (p=0.0428) 
2. Change from baseline in bloati ng: Average change from baseline in Bristol score: -1.8 vs. -0.8 
Vibrant and Sham respectively (p=0.0 345) Sub-group analysis - Average change from baseline 
in bloating: -2.0 vs -0.5 Vibran t and Sham respectively (p=0.0 043) 
3. Change from baseline in straining: Average cha nge from baseline in Bris tol score: -2.3 vs. -
1.5 Vibrant and Sham respectively (p=0.0 824) Sub-group analysis - Average change from 
baseline in straining: -2.8 vs - 1.3 Vibrant and Sham respectively (p=0.0 082) 
4. Responders from both arms used significantly less rescue medication than patients who were 
not responders (p<0.0001 for Vibrant group, p=0.0002 for Sham ): in the Vibrant group, 
responders took a total of 40 days of rescue  medication, and non-resp onders took a total of 
272 days. This confirms that responders were positively affected by the Capsule and needed 
less medication use. When comparing the Vibrant and Sham groups, there was no overall 
significant difference in rescue usage (p=0.5626).  
 
 
Summary results of Subgroup Analysis: 
For the moderate to severe patients, when usi ng the endpoint CSBM (i ncrease of at least 1 
CSBM/week for at least 6 out of 8 weeks of treatment), the sham response rate is significantly 
reduced, and the results reach significance (35.1% vs. 15.0%, p=0.0307). Multiple symptoms were 
significantly improved in the Vibrant arm, compared to sham: the Bristol Stool Score, straining 
and bloating. The Vibrant Capsule showed two to three times the ma gnitude of effect  of the sham 
on each of these endpoints. Other subgroups (mild c onstipation and very severe constipation) were 
moderately improved for endpoints but were never negatively imp acted by the Vibrant Capsule 
 
Conclusions: The Vibrant capsule found to be safe  and effective in sub-group (average weekly 
SBM _1.1 and <2.5 at baseline) compared to sham.  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 29 of 84 
 
 
 
 
Additional study was planned for assess safety and efficacy in an increased administration (V-240) 
 
V-240: "A prospective, multicen ter, randomized, double-blind, Sham -controlled study to assess 
the efficacy and safety of  the Vibrant capsule administered 5 times per week" 
The study was conducted in 25 sites in the USA from Feb 2017 until Jan Dec 2017. 
 
Study design: This study is a prospective, adaptive, multicenter, randomized, double-blind, 
Sham-controlled study  
Study objectives: the purpose of this study is to assess the efficacy and sa fety of the Vibrant 
capsule administered 5 times per week. 
Study population: 182 Subjects with  Functional Constipation refr actory to existing treatments 
with an average of ≥1 and <3 SBMs/week at baseline 
Endpoints: the primary endpoint were safety and efficacy.  
Safety: related AE's/SAE's 
Efficacy: an increase of at least 1 and 2 weekly CSBM from baseline in at least 6 (of 
8) weeks during the treatment period  
The secondary endpoints were:  
1. Change from baseline (run-in pe riod) in average straining. 
2. Change from baseline (run-in period) in av erage stool consistenc y, using the Bristol 
Stool Scale 
3. Change from baseline (run-in pe riod) in average bloating. 
4. SBM success rate, defined as an increase from the run-in period of at least one weekly 
Spontaneous Bowel Movement (SBM) during at  least 6 of the 8 weeks of treatment. 
 
Methods: 5 capsules / week for 8 weeks of treatment 
Results: A total of 88 Adverse Events (AE’s) were reported in the active arm and 50 in the sham 
arm. 2 AE’s were considered serious, 1 in the Activ e arm - a traumatic fracture of pelvis considered 
not related and 1 in the Sham arm - a nxiety attack considered not related.  
 
A summary of adverse events severity is provided below.  
  
  Vibrant Group Sham Group 
Number of 
reports Number of 
subjects IncidenceŦ Number of 
reports Number of 
subjects IncidenceŦ 
Any Adverse Event 88 37 41.57% 50 23 24.73% 
Mild 44 21 23.60%  26 16 17.20%  
Moderate 43 19 21.35%  24 14 15.05%  
Severe 1 1 1.12%  . . . 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 30 of 84 
 
 
 
 
The primary efficacy endpoints results are: –  
1. At least 1 additional CSMB from baseline: 26.4 % vs. 35.8% in the active arm and sham arm, 
respectively (ITT).  
2. At least 2 additional CSMB from baseline : 17.9 % vs. 28.2% in the active arm and sham arm, 
respectively (ITT). 
 
According to the response rate of additional 1CSBM in this study, the increase of the 
administration frequency to 5 capsules per week contribute to the sham group (35.9%) while the 
active group  shows 26.9 % of responder's rate (ITT). The data indicates that the Vibrant sham 
(i.e., Vibrant capsule without vibrations) is an active control, not a pl acebo. The Vibrant sham 
performs better than would be expected for a passive control. The capsule shape, size, and 
persistence in the GI tract is part of the Vibran t therapeutic effect in addition to the vibration  
 
An important pattern was found be tween Frequency of CSBM and the actual time of vibration 
during the day. The pattern is important to unde rstand the mechanism of action of the Vibrant 
capsule and its effect on SBM/CS BM. A clinical correlation was found in this study between the 
time of vibration and CSBM (graph 1).  CSBM fre quency is higher in the active arm compared to 
the sham arm during vibrating time as shown in the graph, and exactly corre lated to the time of 
vibration as preprogrammed for the capsule (1st peak) around 8-12 hours from administration. In 
addition, the active capsule effect is shown agai n 24 hours after activation of same capsule (2nd 
peak around hour 34-36) and suggest  that there is a residual e ffect of the capsule vibration, 
(graph 1). 
 
 
 
 
 
  
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 31 of 84 
 
 
 
 
Graph 1: Vibration during 48 hours 
Subjects in the sham group can be  clearly identif ied in their behavior, as they report CSBM 
immediately after capsule swallowed (time 0 in the above graph). In addition, the sham response 
drops dramatically the next morning, (hours 34- 36), as no additional capsule was administrated 
that morning, while Vibrant active arm is showing superior ity during that time (24 hours from last 
vibration). 
The benefit to subjects during vibration time is cl early shown in the graph below. The percentage 
of CSBM is higher in the active group than in th e sham group, during vibra tion time (see Vibrant 
edge in graph 2)  
 
Graph 2 Correlation between vibration and CSBM 
 
Conclusions: 
 Clean safety profile was maintained as in the previous studies. 
 Minimal AEs were reported during the 8 weeks of treatment, and all those reported were 
either mild or moderate. 
 A clinical correlation was found in this study be tween the time of vibration and Frequency 
of CSBM.   
 CSBM frequency during the capsule's vibrating time is higher for active arm compared to 
the sham arm, and exactly correl ated to the time of vibratio n and near vibration time, as 
preprogrammed for the capsule ar ound 8-12 hours from administration. 
 
An additional study (V-300) was planned to asse ss safety with active capsules in 2 different 
operation modes. The total vibration time of the ac tive capsules will be increased compared to the 
previous study and the vibration occurs in vari ous areas of the colon (m ulti vibration sessions)  
 
 
 
 
 
 
V-300: " A prospective, multi center, randomized, doubl e-blind, sham-control led pilot study to 
assess the efficacy and safety of various vibrating capsule modes" 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 32 of 84 
 
 
 
The study was conducted in 2017- 2018. The enro llment period started on 14/Nov/2017 and the 
follow-up period was completed for the last subject on 14/March/2018.  
Study design: the study is a pros pective, adaptive, multicenter, randomized, double-blind, Sham-
controlled pilot study. This is a 3- arm study: 2 active capsule ar ms (mode 1 and 2) vs. a sham 
capsule arm. 
Study objectives: to assess Safety and efficacy of  the Vibrant capsule administered 5 times per 
week 
Study population: 63 Subjects with Functional Constipation refractor y to existing treatments with 
an average of ≥1 and <3 SBMs/week at baseline. 
Endpoints: the primary endpoint were safety and efficacy.  
Safety: related AE's/SAE's 
Efficacy: an increase of at least 1 and 2 weekly CSBM from baseline in at least 6 (of 
8) weeks during the treatment period  
Methods: The administration was 5 capsules/ week.  The administr ation regimen was 1 
capsule/day on Mondays, Tuesdays, Thursday, Fr idays and Saturdays and 2 days off (Sundays 
and Wednesdays). On Jan 11th 2018 an amendmen t was approved and the weekly capsule 
administration regimen was changed from 5 per/week to 2 per/week. 
 
Results: The results presented are from s ubjects treated with 5 capsules/week.  
Safety: A total of 8 and Adverse Events (AE’s)  in mode 1 and 2, and 4  in the sham arm. 
None of the subjects experienced SAE's or a dverse events related to the Vibrant Capsule 
that required discontinuation.  
Efficacy: In this study, the active capsule used  has multiple vibration sessions compared 
to single vibration session in the V240 study a nd the vibration occurs in various areas of 
the colon. The results in V300 demonstrate the effect of multiple vibration sessions on the 
responder's rate. Improvement by  at least 1 CSBM - 75% of  treatment weeks: 71.43% and 
33.33% vs. 50% in Active mode 1, mode 2 a nd sham respectively. Th e improvement form 
baseline by at least 1 CSBM is  higher in the vibrant capsule mode 1 than in sham capsule. 
 
A final analysis performed at the end of the study on 61 subject. The improvement form baseline 
in SBM/CSBM by at least 1 is higher in the vibr ant capsule (mode 1 and 2) than in sham capsule 
for administration of 5 capsules/week:  
a. SBM - 50% vs. 47.6% vs. 36.3% in Mode 1, mode 2 and sham, respectively for 5 
capsules/week.  
b. CSBM - 50% vs. 38.1% vs. 31.8% in Mode 1, mode 2 and sham, respectively for 
5 capsules/week.   
 
In this study the expected corre lation between vibration and near  vibration time and frequency of 
CSBM repeated itself, as in the previous st udy (V-240). The capsule used was pre-programmed 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 33 of 84 
 
 
 
with multiple vibrati on session. Hence, 2 peaks are show n: 1st peak around 8-12 hours from 
administration followed, a 2nd peak is shown around evening time (graph 3) 
 
 
Graph 3 - Correlation between vibration and freq uency of CSBM – multiple vibration sessions 
 
Conclusions: 
 
1. The active capsule found to be safe, even with  an increased frequency of vibration (in the 
2 different modes), the treatment does not result with side ef fects and retains a very strong 
safety profile. 
2. The results indicate that multiple vibrati on sessions improves efficacy and thus the 
percentage of CSBM was higher in the activ e arm (mode 1) than in the sham arm. 
3. Vibration dose, as an active ingredient to trea t CIC patients, is shown to be more effective 
with patients in V-300 study, compared to ad ministration of 5 cap/ week with a single 
vibration session (lower dose of vibration), in V-240 study.  
4. Mechanism of action is well indicated in V- 300 study (capsule with multiple vibration 
sessions. Hence, 2 peaks are shown around vibrat ion time), whereby higher frequency of 
CSBM is shown during and near vibrat ion time, compared to sham arm. 
5.  The Vibrant capsule stimulates the existing natural mechanism of the GI tract, in a 
mechanical stimulation fashion only, which is different from a drugs, thus no related side-
effects are found for the treatment with vibrating capsule 
 
 
12. STUDY	OBJECTIVE 	
 
The objectives are to assess the efficacy and safe ty of the Vibrant capsule administered 5 times 
per week. 
 
13. STUDY	ENDPOINTS 	
13.1 Primary endpoint 
 
 
Efficacy:  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 34 of 84 
 
 
 
The primary efficacy endpoint is the CSBM success rate, defined as an in crease from the run-in 
period of at least one weekly Complete Spontaneous Bowel Movement (CSBM) during at least 6 
of the 8 weeks of treatment 
• CSBM & SBM is defined as a bow el movement that occu rs at least 48h after 
laxative/rescue intake without digital maneuver)  
• Subjects with less than 2 weeks (with at leas t 5 days per week) of valid diary entries 
during the treatment period will be  considered as non-evaluable.   
 
Safety: 
Safety endpoints include all adverse events related and unr elated to the study treatment 
13.2 Secondary endpoints 
 
Secondary efficacy endpoints include:  
- SBM success rate, defined as as an increase fro m the run-in period of at least one weekly 
Spontaneous Bowel Movement (SBM) during at  least 6 of the 8 weeks of treatment 
Subjects with less than 2 weeks (with at leas t 5 days per week) of valid diary entries 
during the treatment period will be  considered as non-evaluable. 
- Change from baseline in average stool c onsistency, using the Bristol Stool Scale 
- Change from baseline in average straining. 
- PAC-QoL 
 
Additional effciacy endpoints 
- Change from baseline in  average bloating. 
- Number / percentage of subjects who reporte d using rescue medica tion during treatment 
period 
 
- Change from baseline in weekly number of  Spontaneous Bowel Movement (SBM). 
- Change from baseline in weekly number of  Complete Spontaneous Bowel Movement 
(CSBM). 
- Rate of SBM ≤ 24 hours after first dose 
- Change from baseline in average abdominal gas. 
- Change from baseline in average abdominal pain. 
- Change from baseline in abdominal discomfort. 
- Time to occurrence of spontaneous bowel  movement after capsule activation. 
- Ease of use  
- TSQM (validated treatment satisfaction questionnaire) 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 35 of 84 
 
 
 
14. STUDY	CONDUCT 	&	POPULATION 		
 
This study will be performed in accordance with th e design and specific provi sions of this protocol 
, in accordance with the ethical principles that have their origin in the Declaration of Helsinki, that 
are consistent with Good Clinical  Practice (GCP), Title 21 of the Code of Federal Regulations (21 
CFR), part 812 (Investigational De vice Exemptions),  and the app licable regulatory requirements. 
 
14.1 Inclusion Criteria 
 
1. Subjects aged 22 years and older 
2. Subjects with Chronic Idiopathic Constipati on (CIC) according to Rome III criteria and 
who have not experienced relief of their sy mptoms from available therapies (osmotic and 
stimulant laxatives used for at least one month at recommended dose) 
3. Subjects with an average of <3 Spontan eous Bowel Movements (SBM) per week  
4. Normal colonoscopy performed within 5 year s prior to study partic ipation, unless the 
subjects are <50 years old and with out alarm signs and/or symptoms 
5. Subject signed the Inform ed Consent Form (ICF) 
6. Female subjects must have a negative blood pregnancy test  during screening, confirmed 
by a negative urine pregnancy test during base line and must not be lactating prior to 
receiving study medication. For fe males of child-bearing poten tial, a hormonal (i.e., oral, 
implantable, or injectable) a nd single-barrier method, or a double-barrier method of birth 
control must be used throughout  the study. All other female s ubjects must have the reason 
for their inability to bear children documented  in the medical record [i.e., tubal ligation, 
hysterectomy, or post-menopausal (defined as  a minimum of one year since the last 
menstrual period)]; in these circumstances, a pregnancy test will not be necessary.  
 
 
14.2 Exclusion Criteria 
 
1. History of complicated/obstr uctive diverticular disease 
2. History of intestinal or colonic obstruction, or suspect ed intestinal obstruction. 
3. History of significant gastrointestinal diso rder, including any fo rm of inflammatory 
bowel disease or gastrointestinal malignanc y (celiac disease is accepted if the subject 
has been treated and is in remission) 
4. History of gastroparesis 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 36 of 84 
 
 
 
5. Use of any of the following medications:  
o Medications that may affect intestinal motility, prokinetics, anti-
Parkinsonian medications, opiates, opioids, calcium-channel blockers, 
aluminum/magnesium hydroxide 
o With the exception of antidepressants,  thyroid or hormonal replacement 
therapy, when the subject has been on a stable dose for at least 3 months 
prior to enrollment. 
6. Clinical evidence of significan t respiratory, cardiovascular , renal, hepatic, biliary, 
endocrine, psychiatric or  neurologic disease. 
7. Presence of cardiac pacemaker or gastric electrical stimulator. 
8. History of, or current eating disorders, such as anorex ia, bulimia, or compulsory 
overeating. 
9. Diagnosis of mega-rectum or colon, conge nital anorectal malf ormation, clinically 
significant rectocele, history of intes tinal resection (with an exception for 
appendectomy, cholecystectomy and inguinal hernia repair), hi story of bariatric 
surgery or evidence of any structural abnormal ity of the gastrointestinal tract that might 
affect transit 
10. History of Zenker’s diverticul um, dysphagia, Barrett's es ophagus, esophageal stricture 
or achalasia 
11. Chronic use of non-steroidal anti-inflamma tory drugs (NSAIDs): chronic use is 
defined as taking full dose NSAIDs more than three times a week for at least six 
months. Subjects on cardiac doses of aspi rin may be enrolled in the study  
12. Subjects with pelvic floor dysfunction/defecatory disorder , based on subject history 
13. Participation in another clinical study within one month pr ior to screening. 
14. Women who are pregna nt or lactating 
15. Use of any medication for constipation re lief during the study, ex cept as rescue 
medication, as indicated by study rules 
16. Inability to use an electroni c daily Diary (on a computer, phone application, tablet or 
other electronic device) to repor t symptoms and medication usage 
17. Subject participated in a previous Vibrant study 
18. Any other condition which in the opinion of th e investigator may adversely affect the 
safety of the subject or would limit the subject's abil ity to complete the study.  
 
14.3 Duration of Study  
 
Study duration includes at least 2-3 consecutive  weeks of run-in, followed by 8 weeks of 
treatment - Total of at least 10-11 weeks. 
The sample size is calcul ated for up to 60 pts. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 37 of 84 
 
 
 
 
15. STUDY	TREATMENT 	
15.1 Study Design 
 
The study is a prospective, mu lticenter, randomized, single bli nd, placebo-controlled study to 
evaluate the efficacy and  safetyof  Vibrant capsule vs. Vibrant placebo. 
 
The objective is to assess the efficacy and safe ty of the Vibrant Capsule with a frequency of 
administration of 5 capsules per week. 
 
The study will be performed in up to 20 centers in the USA. 
 
Data reporting will be done on an electronic Case  Report Form (eCRF). In addition, subjects will 
fill in daily information about their bowel movements, clinical symptoms and medication usage on 
an electronic Diary (eDiary). The eDiary will be accessed via a computer, smartphone, tablet or 
other suitable device, through a designated website.  
Information about time of activation of the Vibran t Capsules will be record ed automatically by the 
base unit and automatically transferred to a designated website. 
 
Subjects with Chronic Idiopathic Constipation (C IC) according to Rome III criteria who failed 
currently available therapy (defined  as osmotic and stimulant laxativ es used for at least one month 
at recommended dose) and meet the inclusion criter ia will be offered participation in this study. 
The background of the proposed study and its risks and benefits will be explained to the subject 
and the informed consent form will be signed.   
Subjects will be screened for study eligibility ac cording to inclusion and exclusion criteria. The 
daily bowel movements frequency, hi story of constipation, etiology of constipation and medication 
use (including prescription medication) will be throroughly assessed. Subject demographic and 
medical information acquired from the subject or th e subject's medical chart,  including age, gender, 
previous medical history, ri sk factors etc. will be also recorded on the eCRF.  
In addition, subjects will undergo a physical examination including di gital rectal examination, vital 
sign measurements and blood tests.  
 
Rome III questionnaire to confirm the diagnosis of Chronic Idiopath ic Constipation and fill out the 
Bristol Stool Scale questionnaire will be assess ed.  Findings will be recorded on the eCRF. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 38 of 84 
 
 
 
Eligible subjects will then be as ked to refrain from taking any me dication or supplement they are 
using to relieve their constipa tion, and will perform a daily se lf-assessment of their normal 
spontaneous bowel movements for 14 consecutive da ys  (run-in period), utilizing the eDiary. 
Subjects will also be asked to r ecord clinical symptoms and usag e of any medication or supplement 
on the eDiary during th e run-in period.  
 
After the run-in period the subjects will visit the me dical center for the baseline visit. Eligibility 
will be re-assessed and confirme d based on the subject's co mpleted eDiary and Rome III 
questionnaire. The subject will be trained in the medi cal center to use the base unit. He will activate 
himself the first capsule and will in gest it in front of the medical st aff. All the othe r capsules will 
be ingested from the home of the subject. Only th e first ingestion will take place in the medical 
center.  
During the treatment period, subjects will ingest Vibrant Capsule 5 days per week: one capsule on 
Mondays, Tuesdays, Thursdays, Friday  and sate rdays  . Subject will not ingest any capsule 
onWednesdays, and Sundays. The subj ect will ingest a to tal of 40 capsules in 8 weeks considering 
the sequence. 
If the baseline visit falls on a Sunday or Wednesday, the subject should ingest  the first capsule on 
site and skip the next day.  
 
Following this the subject should follow the normal schedule. 
 
Capsule intake will ideally be performed during the evening, between 9 PM and 10 PM (except on 
days where a capsule is  ingested on site). 
 
The subjects will be asked to refrain from taking any medication or supplement they are using to 
relieve their constipation until they complete the study (rescue treatment is allowed as per section 
15.10).  
After 8 weeks, treatment will be ceased and subj ects will visit the medical center one last time for 
evaluation and completion of Rome III que stionnaire and other assessments.   
 
Subjects will be instructed to complete a simple subj ect eDiary throughout th e duration of the study 
starting from the run-in period. This will include daily recordings of capsule intake, number and 
time of bowel movements, clinical symptoms, adverse events, satisfaction score and 
medication/supplements usage, including rescue medication. 
 
Please refer to section 15.15 for a detailed study schedule. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 39 of 84 
 
 
 
Data collection will include physicia n identification, investigational device identification data and 
usage of the capsule. This data will be documented on the eCRF, toge ther with the occurrence of 
any adverse events during the capsule usage. 
 
All subject adverse events (whether device related or not) will be recorded during the course of the 
clinical study. All serious advers e events/complications will be  reported immediately (within 24 
hours) to the study sponsor/monitor , to the Instit utional Review Board and according to the local 
regulatory requirements. 
 
15.2 Medical History 
Subject demographic and medical information acquired from the s ubject or the subject's medical 
chart, including age, gender, weight, hei ght, body mass index (BM I), number of natural 
childbirth and previous medical hi story and medications will be reco rded, including: a history of 
clinically significant ab normalities of all body systems; conc urrent diseases; relevant past 
medical history.  
The information will be recorded in the eCRF for all subjects participating in this study.  
15.3 Constipation History 
Full history of constipation will be recorded on the eCRF, including duration of constipation, full 
history and habits of medicati on (over the counter and prescr iption) and supplements use, 
frequency of spontaneous bowel, current medication/ supplements use, descri ption of current diet 
(with focus on water intake and fiber intake), physical activity  (number of hours of physical 
activity per week), recent ch ange in bowel movements. 
15.4 Physical Examination 
During the screening visit all subjects will unde rgo a conventional physical examination by an 
authorized physician. The physical examination will include diagnosis and documentation of any 
significant abnormalities or diseases. The physical  examination will incl ude a digital rectal 
examination. 
15.5 Assessment of pelvic floor dysfunction (defecatory disorder) 
Assessment of pelvic floor dysfunction will be ba sed on subject history. Subjects with suspicion 
of pelvic floor dysfunction will be excluded. 
If subjects have been previously diagnosed w ith pelvic floor dysfunction following anorectal 
manometry, a balloon expulsion test, or other examinations, docume nted results from these tests 
can be used to exclude subjects.   
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 40 of 84 
 
 
 
15.6 Blood and urine tests 
During the screening visit all subjects will underg o the following blood tests: blood count, calcium, 
creatinine, Blood Urea Nitrogen (BUN), sodium, pot assium and TSH. Blood pregnancy test will 
be performed during the screeni ng visit. A pregnancy urine test  will be performed during the 
baseline visit. 
15.7 Screening visit (day -21 to -14) 
At the screening visit, subjects will be evaluated for eligibilit y and undergo physical examination, 
digital rectal examination, vital sign measuremen ts and blood tests. They will undergo a thorough 
interview about their constipati on and the Rome III questionnair e (see appendix B) will be 
completed. The Bristol Stool Scale (see Appendix  A) and PAC-QOL (see Appendix E) will also 
be completed by the subject.  
 
The investigator will confirm their eligibility and their physical and mental su itability to participate 
in this study.  
Subjects exiting the trial at this stage will be cons idered screening failure subjects and be replaced 
with new subjects. 
 
The subject will be trained by the study c oordinator to access and use the eDiary.  
The eDiary contains questions about bowel movements and their associated clinical symptoms 
(straining, abdominal pain, abdominal discomfort , abdominal gas, bloa ting, need for digital 
maneuver, sensation of complete  evacuation), usage of rescue medication, adverse events and 
usage of other medication or supplements (name of drug, dosage, number of takes per day, reason 
for medication).  
The information will be transf erred to the eCRF every day.  
 
The subject will define his/her preferred device to  use the eDiary. The subject and study coordinator 
will define together the time of the day during whic h the subject will fill in the eDiary and a daily 
alert will be set up on the phone of the subject. The daily diar y can be found in Appendix D. 
  
15.8 Run-in period (day -21 to -14, to -1) 
Eligible subjects after screening, will be observed and monitored for the first 2 weeks, in which 
they will be asked to refrain from taking any medication or supplement to relieve their constipation. 
On the day of screening, the coordinator should de termine with the subject the last day of intake 
of constipation medication/aid and ensure that the last intake of  constipation medication/aid has 
been taken more than 48 hours before the firs t diary entry. 
Subjects will complete the eDiary every day and there should be a pe riod of at least 14 consecutive 
days between the first day the subject fills in the diary and the last day of run-in period. The run-
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 41 of 84 
 
 
 
in period may be extended by a few da ys in case of technical issue (difficulty to access eDiary), to 
allow for a wash-out period, or other. The r un-in period may be extended by up to 7 days. 
The last 14 consecutive days of the eDiary will be monitored to determine eligibility of the subjects. 
 
 
The subjects will receive at least 1 short phone call/week from the study coor dinator, if needed.  
The phone calls will be about 5-10 minutes long and will ask check subject compliance with the 
eDiary, occurrence of adve rse events, and use of rescue medi cation, subject understanding of what 
he needs to do in the context of the study and discu ss any issue or difficulty that the subject might 
have. Confirmation of date and time of the phone call will be reported on the eCRF. 
 
If a subject does not fill in his/ her eDiary, the sponsor/investigator  will be alerted and the subject 
will be contacted by phone call in order to rece ive more information and gather the missing 
information. Compliance of the subj ect will be closely monitored. 
Subjects who fail to fill in  their diary 3 times or more (not du e to technical issues) during the run-
in period may be considered as screeni ng failures due to lack of compliance. 
15.9 Treatment 
On day 0 (baseline visit), the subject will arrive  to the clinic. Eligibility will be re-assessed and 
confirmed based on the Rome III questionnaire and on the subject's completed diary. Subjects need to have an average of less than 3 SBM per week during the tw o weeks of run-in..  
 
Eligible subjects wi ll be randomized to: 
- Vibrant arm –with a freque ncy of administration of  5 capsules per week, OR  
- Vibrant Placebo arm –with a frequency of  administration of 5 capsules per week  
 
Treatment duration is 8 weeks. 
The subject will be trained by the study coordinator to use the base unit and activate the capsules. 
After an oral explanation, the s ubject will read the base unit user  manual, and the study coordinator 
will make sure the subject fully understands how to use the base unit. The subject will then activate 
the first capsule, in front of the study coordinator, and swallow it.  
The subject will then be released home with the base unit and capsu les for the first four weeks of 
treatment. The subject will be asked to continue w ith the daily completion of the eDiary. The first 
2 weeks of treatment will be consid ered as a subjects’ training period. 
Actual point of enrollment fo r the subject is considered th e day of first capsule intake. 
 
Subjects will be asked to refrain from any medication or supplement they are using to relieve their 
constipation, throughout the treatment period. A re scue treatment will be authorized upon need 
(refer to section 15.10 for details).  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 42 of 84 
 
 
 
 
Capsule intake should take place ideally dur ing the evening between 9 PM and 10 PM, on 
Mondays, Tuesdays, Thursdays, Fridays and Saturdays.  
The first intake, which will take place in the me dical center during the da y, will not follow these 
rules.  
 Capsule distribution for the subject will be in 2 time points: 
- Day 0 (baseline visit): capsules for 4 weeks of treatment will be provided  
- Day 28 ± 2 days (treatment visit 1): capsules for 4 weeks of treatment will be provided  
 
The subjects will receive at least one phone call per week from the study coordinator.  
The phone calls will be about 5-10 minutes long a nd will check subject compliance with capsule 
ingestion and the eDiary, occurrence of advers e events, use of rescue medication, subject 
understanding of what he/she need s to do in the context of the study and discuss any issue or 
difficulty that the subject might have. Confirma tion of date and time of the phone call will be 
reported on the eCRF. 
Compliance of the subject will be closely monitored.  
 
Overall the subject will visit the site once during the treatment period: 4 weeks after the baseline 
visit. The last visit will be 4 weeks after baseline  and will be the terminati on visit. The subject will 
receive the capsules in  2 separate visits: 
- Baseline visit: 20 capsules for 4 weeks of treatment  (5 capsules for each week) and a spare 
blister with 10 capsules 
- Visit 1 during treatment period: 20 capsules for 4 weeks of treatment  (5 capsules for each 
week). 
The subject will receive 1 blister of spare capsules at the baseline visit and must bring back to the 
site all remaining capsules in his/her possession fo r each visit. The capsules must be counted and 
accounted for. 
During each visit, an interview wi ll be conducted, where the following  topics will be discussed: 
occurrence of adverse events, comp liance to filling in the daily information on the eDiary and to 
the treatment, concomitant medication/rescue taken, evolution of constipation symptoms, subject’s 
perceptions about the treatment, motivation of the subject, or  any other topic relevant.  
 
 
15.10  Rescue Treatment 
 
Subjects will stop using all medi cation or supplement to relieve constipation during the entire 
study period and comply to use c onstipation aid only for rescue.  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 43 of 84 
 
 
 
Using one rescue medication is authorized on ly after 3 consecutive days without a bowel 
movement and under the rules described below. Th e subjects will not be required to contact the 
investigator prior to taking any medication/supplem ent but they will be requi red to declare all the 
rescue medication on their eDia ry. The following treatment is recommended (not by order): 
1. Dulcolax® suppository/b isacodyl suppository 
2. Fleet Enema® 
3. Dulcolax®/bisacodyl tablet (1x5mg) 
 
The subject is allowed to take a rescue medication/s upplement that is not in the above list, 
without contacting the inve stigator. The subject must declare all rescue intake in the eDiary. 
In a situation where the investigator prescribes a rescue medi cation/supplement that  is not in the 
above list, the investigator will need to menti on it and give the reason in a note to file or 
appropriate form. 
 
Subjects who take rescue medicat ion three times or more duri ng the run-in period will be 
considered as screening failures. 
 
A spontaneous bowel movement is defined as a bowel movement th at occurs at least 48h after 
laxative/rescue intake and without digital maneuver. 
A complete spontaneous bowel movement is defined as a spontaneous bowel movement 
associated with a feeling of co mplete evacuation by the subject. 
 
15.11  Termination visit 
After 8 weeks, treatment will be ceased. Subjec ts will visit again th e medical center for 
evaluation and completion of the, ease of us e questionnaire, PAC-QO L, TSQM (Treatment 
Satisfaction Questionnaire for Medication)16 , termination form and end of study form. The 
subject will be evaluated for occurrence of adve rse events, concomitant medication/rescue and 
compliance to the eDiary and treatment. 
The subjects will bring back all remaining capsule s in their possession as well as the base unit. 
The capsules must be count ed and accounted for. 
 The ease of use , PAC-QOL questionnaires a nd TSQM can be found in Appendix C E and F 
respectively. 
15.12  Concomitant medication 
All medication taken by the subject in additi on to the investigational device is termed 
concomitant medication.  All concomitant medication taken duri ng the study must be 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 44 of 84 
 
 
 
documented in the case report form  (name of drug, date  of intake, dosage, number of takes per 
day, reason for medication). The su bject will fill in all the info rmation daily on the eDiary.  
15.13  Prohibited medication 
The medications listed below will be prohibited during the entire study:  
- Medications that may affect intestinal motility  
- Prokinetics 
- Anti-Parkinsonian medications 
- Opiates 
- Opioids 
- Calcium-channel blockers 
- Aluminum/magne sium hydroxide. 
 
Chronic use of non-steroidal anti-i nflammatory drugs (NSAIDs) is also prohibited. Chronic use is 
defined as taking full dose NSAIDs on a regular ba sis (i.e. more than three times a week) for at 
least six months.  
Subjects on cardiac doses of aspiri n may be enrolle d in the study.  
 The following medications are equa lly prohibited, but with an excep tion when the subject has been 
on a stable dose of the medi cation for at least 3 months: 
- Antidepressants 
- Thyroid or hormonal re placement therapy. 
15.14  Recording 
All tests will be performed prior to procedure in case where not already done per routine hospital 
protocol. Device handling and function will be recorded.  
The standard treatment and care pr ovided to all subjects, alongsid e the Vibrant capsule and other 
treatments will be perform ed and recorded on the appropriate study eCRF.  
The subject will be questioned on his clinical st atus, the presence of any medical intervention 
performed since the last visit and any adverse even ts or discomforts. When necessary, the subject 
will be asked to arrive for a follow-up visit at the clinic. 
15.15  Study Schedule   
Table 1 summarizes the required data collection from assessments and tests performed during the 
study. 
 
Procedures Screening Baseline Treatment 
visit 1 Termination 
visit   
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 45 of 84 
 
 
 
Visit No.  1 2 3 4   
Day -21 to -14 0 28 (±2 days) 56 (±2 days)   
IC +      
Eligibility Criteria  + +     
Physical Exam  +      
Digital Rectal Exam  +      
Vital Signs  +      
Blood test  +      
Urine Pregnancy test (if 
applicable)  +     
Administration of 
capsule   +     
Rome III  + +     
Bristol Stool  +      
PAC-QOL +   +   
TSQM & Ease of use    +   
Subject eDiary  + + + +   
Adverse Events  + + + +   
Concomitant Medication  + + + +   
Table 1  – Study Schedule of Assessments 
 
15.16  Deviations from study protocol 
 
Any deviation from the study protocol should be  notified to the sponsor, documented on study 
deviation forms and reported to th e Ethics Committee as required. 
 
Protocol deviations related to  treatment compliance (e.g. mi ssed capsule, capsule taken on a 
Wednesday or Sunday, etc.) will not be declared on the protocol deviation form accessible via the 
EDC (Electronic Data Capture). Protocol deviations related to  treatment compliance will be 
monitored and declared by the Spon sor, CRO and sites using a platform external to the EDC. This 
external platform will use the information transmitted from th e base units about activations (base 
unit serial number, date and time of activation,  success/failure) as a basis to monitor treatment 
compliance. 
Additional information transmitted by the subjec t from the eDiary about number of capsules taken 
out of the blister and swallowed for each day, as we ll as direct information given by the subject to 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 46 of 84 
 
 
 
the study coordinator by phone, email or SMS, w ill be used by the Sponsor and CRO to make a 
final decision about treatment compliance, for each day of treatme nt, for all subjects. 
A final list of protocol deviations related to trea tment compliance will be issued at the end of the 
study, from the external platform, and signed by the si te. This list will be considered equivalent as 
protocol deviations forms. The site will not manua lly enter these protocol deviations in the EDC. 
 
15.17  Investigative Center Selection Criteria 
 
The investigative site will meet the following selection cr iteria prior to incl usion in this study: 
 Clinical research study experi ence and resources that demons trate good compliance with 
study requirements and timel y, complete documentation of subject follow-up.   
 Sufficient subject volume to meet enrollment timeframe. 
16. ADVERSE 	EVENTS	RECORDING 	
 
At each evaluation, the investigator will deter mine whether any adverse events (AE’s) have 
occurred. All adverse events occurring during the study will be recorded on the appropriate case 
report form page by the investigator .  The nature, severity and relation of the adverse event to the 
study device will be documented.  
16.1 Reporting Requirements 
Timely and complete reporting of Adverse Ev ents (AE) and safety assessment allows: 
 Protection of safety  and study subjects. 
 Greater understanding of th e overall safety profile of the study treatment. 
 Appropriate modification of study protocols and improve ment in study design and 
procedures. 
 Adherence to regulatory requirements. 
The definitions and reporting requ irements adopted in this study are derived from the current 
International standard on clinical investigations : Title 21 of the Code of Federal Regulations (21 
CFR), part 312 (Investigational New Drug Applic ation), Section 32 (IND Safety Reporting) and 
part 812 (Investigational Device Exem ptions), Secti on 150 (Reports). 
16.2 Definitions  
Adverse Events (AE) 
AE is defined as any untoward medical occurrence in  a subject. This definition does not imply that 
there is a relationship between the adverse event and the device under investigation.  An AE can 
therefore be any unintended sign, symptom, diseas e or injury or any untoward clinical signs 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 47 of 84 
 
 
 
(including an abnormal laboratory findings) in subjects, users or other persons whether or not 
related to the investigationa l medical device. The following should be reported as AE: 
 Untoward medical conditions or  signs or symptoms that were  absent before starting study 
treatment. 
 Untoward medical conditions or  signs or symptoms present be fore starting study treatment 
and worsen (increase severity or fre quency) after starting study treatment. 
 Abnormal laboratory findings. 
 Clinical signs or symptoms that require therapy. 
 Device Deficiency  
Device Deficiency is defined as Inadequacy of a medical device related to its identity, quality, 
durability, reliability, safety or performance, such as malfunction, mis use or use error and 
inadequate labeling. A final list of  device deficiency will be issu ed at the end of the study, from 
the external platform, and signed by the site.  
 
Adverse Device Effect (ADE) 
ADE is adverse event, related to the use of an investigational medical device. This includes any 
adverse event resulting from insufficiencies or in adequacies in the instructions for use or the 
deployment of the device, the operation, or any ma lfunction of the investig ational medical device, 
device failure or misuse, and any event that is a result of a user error. 
 
Device failures, Malfunctions and Misuse 
Investigators are instructed to report all possi ble device failures or mi suse observed during the 
course of the trial. These incidents will be documented in the case report form provided as 
follows: 
 
 Device Failure  - A device failure has occurred when the device is used in compliance 
with the Instructions for Use,  but does not perform as descri bed in the Instructions for 
Use. A device failure occurs when  
o A capsule fails to activate.  
o The transmission about the first capsule activation cannot be performed (during 
the baseline visit) by the base unit. This event must lead to the replacement of the 
base unit.  
o The base unit loses its ability to tran smit information permanently. This event 
must lead to the replace ment of the base unit. 
Device Misuse  - Any use of the investig ational device by an investig ator or subject that is 
contradictory to the application described in the Instructions for Use will be categorized 
as device misuse.  
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 48 of 84 
 
 
 
 
Serious Adverse Events (SAE) 
A SAE is an adverse event that: 
1.     Led to a death, 
2.     Led to a serious deteriorati on in the health of the subject that: 
a. Resulted in a life-threatening illness or injury 
b. Resulted in a permanent impairment of  a body structure or a body function 
c. Required in-subject hospitaliz ation or prolongation of existing hospitalization  
d. Resulted in medical or surgical interven tion to prevent permanent impairment to 
body structure or a body function. 
  3.    Led to fetal distre ss, fetal death or a congenital abnormality or birth defect. 
 
Device deficiencies that might have led to a SAE if a suitable action had not been taken or 
intervention had not been made or if circumstances had been less opportune are also handled 
under the SAE reporting system.  
However, planned hospitalization for pre-existi ng condition and/or proced ure required by the 
clinical trial protocol, without se rious deterioration in health, is  not considered to be a SAE. 
 
Serious Adverse Device Effect (SADE) 
A Serious Adverse Device Effect is an adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event. 
 
Unanticipated Serious Adv erse Device Effect (USADE) 
USADE is defined as serious adve rse device effect which by its na ture, incidence, severity or 
outcome has not been identified in the current version of the ri sk analysis report or other study 
related documents.  
 
16.3 Anticipated Adverse Events 
The Vibrant Capsule targets pa thophysiological parameters of chronic constipation by inducing 
natural bowel activity without using chemical supplements. 
Anticipated Adverse Events include those that ar e reasonably expected to occur in association 
with a clinical investig ation assessing a treatment for function al constipation. Events can occur as 
a result of the disease or as a result of the treat ment (including usage of the home base unit). They 
may include but are not limited to the following (in al phabetical order): 
 Abdominal pain/discomfort/cramping 
 Blood in the stool may develop or increase 
 Bloating/Flatulence 
 Diarrhea  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 49 of 84 
 
 
 
 Nausea may develop or increase 
 Rectal pain may de velop or increase 
 Sensation of vibration in the abdomen 
 Uncontrolled leakage of stool may occur 
 Vomiting may develop 
 
All events listed above, and additional events that the investigator will evaluate will fit the 
definition of ‘anticipated event’, will be categorized as such in the study. 
16.4 Adverse Event Reporting 
All adverse events and adverse device effects occu rring during the clinical trial must be recorded 
by the investigator on the appropriate AE form in  the eCRF, within a reasonable time (up to 5 
calendar days from investigator's awareness of the event). All AEs will be characterized by the 
following criteria: 
 Intensity or Severity 
 Relatedness 
 Outcome 
 Treatment or Action Taken. 
 
16.4.1  Intensity or Severity 
The following categories of the intensity of  an adverse event are to be used:  
Mild  – Awareness of a sign or symptom that does not  interfere with the subject’s usual activity 
or is transient, resolved without  treatment and with no sequelae. 
Moderate  – Interferes with the subject’s usual activity and/or requires symptomatic treatment. 
Severe  – Symptom(s) causing severe discomfort and significant im pact of the subject’s usual 
activity and requires treatment.  
16.4.2  Relatedness 
The investigator will use the following definitions to assess the relationship of the AE to the 
investigational medical device: 
Not related  - The cause of the AE is known and the ev ent is not related to  the investigational 
medical device. 
Possibly related  - There is a reasonable possibility that the event may have been caused by the 
investigational medical device. 
The AE has a timely relationship to the study procedure(s); however, follows no known pattern 
of response, and an alternative cause seems more likely or there is significant uncertainty about 
the cause of the event.  
Probably related  - It is likely that the event was cau sed by the investigational medical device. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 50 of 84 
 
 
 
The AE has a timely relationship to the study procedure(s) and follo ws a known pattern of 
response; a potential alternative cau se, however, may explain the event. 
Related  - A related event has a strong temporal rela tionship and an alterna tive cause is unlikely. 
 
16.4.3  Outcome 
The clinical outcome of the AE or SAE will be characterized as follows: 
Death  - The SAE CRF must be completed for th is outcome (see 16.5 Expe dited Reporting of 
Serious Adverse Events). Recovered without sequelae  - The subject returned  to baseline status 
Ongoing  - Subject did not recover and symptoms continue 
Recovered with sequelae  - The subject has recovered but wi th clinical sequelae from the event 
Unknown  - The subject outcome is unknown 
 
16.4.4  Treatment or Action taken 
The treatment or action taken after the occurr ence of an AE or SAE will be reported as: 
Interventional Treatment  - Surgical, percutaneous or other procedure 
Medical Treatment  - Medication frequency of adminis tration reduction/interruption or 
discontinuation, or medica tion initiated for event 
None  - No action is taken 
 
16.5 Expedited Reporting of Serious Adverse Events 
Any Serious Adverse Event, and device deficiencies  should be reported to Vibrant Ltd. within 24 
hours of investigators' knowledge of the event. Investigator s hould report these events on the 
appropriate SAE form / Device De ficiencies Form in the eCRF and send the form by fax or e-
mail, to the following safety contact person: 
 
Lior Ben Tsur 
Vibrant 
Hakochav 
Yokneam 2069206 
P.O.Box 516, Israel 
Tel: +972-46-663322 
Cell: + 972-54-6950001 
Lior.b@vibrantgastro.com  
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 51 of 84 
 
 
 
If applicable, the investigator shou ld also inform the representative  of the appropria te local Ethics 
Committee, within 24 hours of inve stigator's awareness of the event. A copy of the report cover 
letter should be filed within the study file.  
  
The sponsor is responsible for the ongoing safe ty evaluation of the i nvestigational medical 
device. The sponsor will promptly notify all co ncerned investigator(s)/institution(s) and the 
regulatory authority(ies) of findi ngs that could affect adversely th e safety of subjects, impact the 
conduct of the trial, or alter the Medical Et hics Committee approval/ favorable opinion to 
continue the trial. 
 
The sponsor will expedite the reporting to all co ncerned investigator(s)/institutions(s), to the 
EC(s), where required, and to the regulatory au thority(ies) of the occurrence of Unanticipated 
Serious Adverse Device Effects.  
 
16.6 Follow- Up of Unresolved Events 
All adverse events should be followed until they ar e resolved or the subject’s participation in the 
study ends.  
	
17. STATISTICAL 	CONSIDERATIONS 		
17.1 Study Design and Objectives 
 
The study is planned as a prospective, multicenter,  ra ndomized, single blind, placebo-
controlled study, designed to assess the effi cacy and safety of the Vi brant capsules vs. placebo.  
After a run-in period of 14-21 days , subjects will be randomized w ith a ratio of 1:1 to either 
active capsule, or placebo capsule. The subjects w ill then be treated with the active Vibrant or 
placebo capsule for 8 weeks. The first 2 weeks of  treatment will be considered as a subjects’ 
training period. One interim analys is is planned after all the su bjects will complete the first 4 
weeks of treatment.  
Data from this study may be combined with da ta from the company’s upcoming V-310 study since 
they both will follow the same protocol. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 52 of 84 
 
 
 
17.2 Study Endpoints 
 
 The study endpoints are de tailed in section 13 
17.3 Statistical Hypothesis 
 
 In this study, statistical analys es of safety and efficacy measures  will be mainly descriptive in 
nature, no hypothesis will be tested. 
17.4 Sample size 
No formal sample size calculations were perform ed. A sample size of up to 60 subjects including 
a potential ~10% drop-out rate.  (30 in each arm) is  deemed sufficient to fulfill the main goals of 
the study. 
 
  
17.5 Interim Analyses 
 One interim analysis is planned, after all th e subjects will complete the first 4 weeks of 
treatment.  
 
17.5.1      Procedure 
After all the relevant data will be entered into th e database, and the database cleaned, a soft lock 
to the database will be performed. An indepe ndent un-blinded statistician (not the study 
statistician) will perform the a ssessments described below.  
The primary efficacy endpoint will be adjusted fo r the interim analysis. The efficacy endpoint for 
the interim analysis is the adjusted CSBM success rate, defined as an increase from the run-in 
period of at least one weekly Complete Spontaneous Bowel Movement (CSBM) during at least 3 
of the 4 first weeks of treatment. For each analysis set, the adjusted CSBM succe ss rate will be presented in a tabular form by 
study arm, along with 95% Wilson sc ore Confidence Intervals (CI). 
17.5.2  Blinding 
ONLY the un-blinded statistician will be expose d to the subjects’ treatment allocation. . 
Investigators and company directors will only be exposed to the adjusted CSBM success rates 
(and CI’s) for each analys is set and study arm. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 53 of 84 
 
 
 
17.5.3  Decision Rules 
The sponsor reserves its right to  stop the study due to futility, safety issue,  or for any other 
reason. 
  
 
 
 
17.6 Randomization 
 
After a subject meets the eligibility criteria, he/she  will be equally allocated (with a 1:1ratio) to one 
of the following treatment groups ba sed on a randomization scheme with  fixed blocks stratified by 
center:  
• Active capsule  administered 5 times per week 
• Placebo capsule  administered 5 times per week 
The randomization scheme will be prepared by BioStats using the SAS® (version 9.4.) random 
number generating procedure. 
17.7 Blinding 
This is a single blind study, the subjects, and the evaluators will be b linded to the treatment 
allocated to each subject. 
17.8 Data Analysis Sets 
17.8.1  Intent to Treat (ITT) 
The ITT analysis set will consist of all s ubjects randomized. In accordance with the ITT 
principle, all subjects randomized  will be kept in their original ly assigned treatment group for 
analysis. Subjects with no valid post baseline asse ssment will not be part of  the relevant analysis. 
17.8.2  Modified Intent to Treat (mITT) 
The mITT analysis set will consist of all randomi zed subjects who met the inclusion criteria of 
the protocol. In accordance with the ITT principle,  all subjects randomized will be kept in their 
originally assigned treatment group. Subjects with no valid post baseline assessment will not be 
part of the relevant analysis. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 54 of 84 
 
 
 
17.8.3  Per-Protocol (PP) 
The per-protocol analysis set will consist of all subjects from the mITT analysis set without 
major protocol violations and successfully comple ted the study, with treatment group analyzed as 
treated. 
17.8.4  Statistical Analysis of Analysis Sets 
The ITT analysis set will serve as the main set for safety assessments . 
The efficacy assessment will be presented on the ITT, mITT and PP analysis sets . 
17.9 Statistical Analysis 
17.9.1  General Considerations 
Statistical analyses will be performed using SAS® v9.4 or higher (SAS Institute, Cary NC, 
USA) . 
Baseline demographic and other baseline characteris tics, together with safety analyses will be 
performed on all enrolled subjects. Baseline values  are defined as the last  valid value prior to 
treatment . 
The efficacy and safety endpoints are mainly descriptive in nature. 
Nevertheless, if statistical tests will be performe d, they will be two-sided and nominal p-values 
will be presented. Where confidence limits ar e appropriate, non-adjusted two-sided 95% 
confidence interval wi ll be constructed. 
For comparison of means (continuou s variables), the two-sample t- test or the Wilcoxon rank sum 
test will be used as appropriate.  For comparison  of proportions (categori cal variables), the Chi-
squared test or Fisher’s exact te st will be used as appropriate . 
17.9.2  Significance levels and handling of type I error 
17.9.2.1  Type I Error 
The significance level for this study is 5% usi ng two-tailed tests. The endpoints are mainly 
descriptive in nature, no adjustment fo r multiple testing will be performed.  
  
17.9.3  Demographic and Other Baseline Variables 
Demographic and baseline condition related characteristics will be tabulated. Continuous 
variables will be summarized by a mean, standard deviation, min imum, median and maximum, 
and categorical variables by a count and percentage. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 55 of 84 
 
 
 
17.9.4  Disposition of Subjects 
Treatment tolerability will be presented by treat ment groups, the number and percent of subjects 
who fail to complete the study and the number and percent of subjects who fail to complete the 
study because of Adverse Events will be presente d. Time to withdrawal will also be assessed and 
presented by Kaplan-Meier curves and will be compared using the Log-Rank test if relevant. 
17.9.5  Efficacy Analysis 
   Main Efficacy Analysis: 
Statistical analyses will be mainly descriptive in nature.  
The subject’s CSBM success status (i.e. if the subjects achieve an increase from baseline of at 
least 1 weekly CSBM during at least 6 out of the 8 treatment weeks) will be presented in tabular 
form by study arm, along with 95% W ilson score Confidence Intervals (CI). 
 
 
The SBM success rate will be analyzed in the same manner. 
 
The change from baseline in number of weekly CSBM will be modeled with an Analysis of 
Covariance (ANCOVA) model, wi th baseline weekly number of CSBMs and site entered as 
covariates. The adjusted means of the change  from baseline per study ar m, and the difference 
between the groups will be presen ted along with respective 95% CI. 
 
The change from baseline in count of weekly SB M, and in symptoms w ill be analyzed with 
similar ANCOVA models, with their respec tive baseline values as covariate. 
 
 
Time to occurrence of SBM after intake of the first Vibrant capsule (eit her active or sham) will 
be assessed and presented by Kapl an-Meier curves and will be compared between the study arms 
using the Log-Rank test if relevant. 
 
Treatment satisfaction, and ease of use will be presented in tabular form. 
17.9.6  The PAC-QoL, the rescue medication use, and the 
rate od SBM during the first 24 hours after the first dose will be presented in tabular 
form. Treatment by Center Interaction 
It is expected that only a few subjects will receive each study treatment per site, therefore it will 
not be possible to assess the treatment by cente r interaction. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 56 of 84 
 
 
 
17.9.7  Safety Analysis 
Adverse events (AE) will be presented by seri ousness, severity and relation to treatment by 
treatment group. The number of repo rts, the number of subjects, and the incidence (percent of 
subjects) will be tabulated by study arm. 
17.9.8  Handling of Missing Data 
 
Subjects with less than 6  weeks of diary data w ill be considered as fa ilures for the CSBM and 
SBM success rates. 
 
  
 
For the time to first SBM analys is, subjects with no known SBM will be considered left censored. 
For the analyses of the other endpoints, no imp utations for missing valu es will be performed. 
 
18. DATA	MONITORING 	PLAN		
The Principal Investigator and his study staff will  monitor all data accrual. In addition a data 
monitor will visit the study site during the study and re view the progress of the clinical trial 
including safety data and ensu re as possible that it is conduc ted, recorded, and reported in 
accordance with the protocol, Good Clinical Pr actice (GCP), and the applicable regulatory 
requirement(s). A written report form will be issued after each monitoring visit (including 
initiation and close out visits). The monitoring visit report will include a summary of what the 
monitor reviewed and the monitor's statemen ts concerning the signi ficant findings/facts, 
deviations and deficiencies, conclusions, acti ons taken or to be taken and/or actions 
recommended to secure compliance. The invest igator/institution should pr ovide direct access to 
source data/documents for trial -related monitoring and auditing, IRB/IEC review and inspection 
by the appropriate regulatory authority/ies.  
 
NOTE: e-Source may be used. 
 
Verification during monito ring visit will include: 
 
1. That the investigator has adequate qualific ations and resources and remains adequate 
throughout the trial period, that facility, including laboratories,  equipment, and staff, are 
adequate to safely and properly conduct the trial and remain adequate throughout the trial 
period. 
2. Verifying for the inves tigational product(s): 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 57 of 84 
 
 
 
a. That storage conditions are acceptable. 
b. That the investigational product(s) are suppl ied only to subjects w ho are eligible to 
receive it according to prot ocol and no other use is be ing done with the Vibrant 
devices. 
c. That the receipt, use, and return of th e investigational produc t(s) at site are 
controlled and documented ad equately and that supplies delivery notes are 
confirmed upon reception throughout the trial. 
d. That the unused investigational product(s) at sites will be returned. 
3. Verifying that the investigator  follows the approved protocol  and all approved amendment(s), 
if any. 
4. Verifying that written informed consent was obt ained before each subject's participation in 
the trial. 
5. Ensuring that the investigator receives the curre nt Investigator's Broc hure, all documents, and 
all trial supplies needed to c onduct the trial properly and to comply with the applicable 
regulatory requirement(s). 
6. Ensuring that the investigator a nd the investigator's trial staff are adequa tely informed about 
the trial. 
7. Verifying that the investigator and the investigator's trial staff are performing the specified 
trial functions, in accordance with the protocol  and any other written agreements, and have 
not delegated these functions to unauthorized individuals. 
8. Verifying that the investigator is  enrolling only eligible subjects  and at sufficient recruitment 
rate. 
9. Verifying that source document s and other trial records are accurate, complete, kept up-to-
date and maintained. 
10. Verifying that the investigator provides all the required repor ts, notifications , applications, 
and submissions, and that these documents are accurate, complete , timely, legible, dated, and 
identify the trial. 
11. Checking the accuracy and completeness of th e CRF entries, source documents and other 
trial-related records against each other.  
12. The data required by the protoc ol are reported accurately on the CRFs and are consistent with 
the source documents. 
13. Adverse events, concomitant medications and intercurrent illnesses are reported in 
accordance with the protocol on the CRFs. 
14. Visits that the subjects fail to  make, tests that are not conduc ted, and examinations that are 
not performed are clearly re ported as such on the CRFs. 
15. All withdrawals and dropouts of enrolled subjects from the tria l are reported and explained on 
the CRFs. 
16. Verifying that the investigator had answered all of the queries  that came up from inspection 
of the CRFs or other trial material. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 58 of 84 
 
 
 
17. That the investigator is maintaining the essential documents.  
18. Verifying that deviations fro m the protocol, SOPs, GCP, a nd the applicable regulatory 
requirements are reported by the investigator to  the IRB/IEC and that appropriate actions 
were taken to prevent recurren ce of the detected deviations. 
 
Should there be an unexpected number of device fa ilures or related complications that increase 
the risks to the participants, or critical efficacy endpoints at inte rvals that are not satisfying, the 
study will be halted and analysis performed to  determine whether to continue, modify the 
protocol, or close the study. 
 
19. DATA	CONFIDENTIALITY 		
 
Each subject will be identified by his/ her initi als and a unique subject identification number. 
Source data will be stored with source documents. The Investigator Site Files (ISF) will be held 
in a secure area. The subject’s name and personal data will remain confidential and will not be 
published in any way. However, the sponsor’s monitor or representative and regulatory 
representatives, auditors and inspectors may ha ve access to medical files in order to verify 
authenticity of data collected. 
 
20. FUNDING 		
 
The study is funded by Vibrant Ltd.  
21. ETHICS		
 
Prior to study initiation the si te shall obtain EC or IRB appr oval of the study. A copy of the 
written EC approval must be provided to th e sponsor prior to the start of the study. 
Any changes in the study protocol, informed consen t forms, or investigator  must be re-approved 
by the EC or IRB and the approval documented. A ll subjects enrolled in the study will provide 
their consent prior to en tering the study. An informed consen t form shall be signed and dated by 
the subject. The investigator will retain the forms as pa rt of the study records.  
This study will be executed in a ccordance with the Declaration of Helsinki, in agreement with the 
guidelines for conducting a clinical investigation in accordance with the principles of ICH GCP 
outlined in the E6 document. By signing the presen t protocol, the investigator commits to carry it 
out in accordance with lo cal legal requirements. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 59 of 84 
 
 
 
Other investigator responsi bilities relative to the EC include the following: 
1. During the conduct of the study, the investigator  will submit progress reports to the EC as 
required, and request re-review and appr oval of the study at least once a year; 
2. The investigator will report immediately to th e EC of any unexpected serious adverse events 
that occur during the study, a nd provide the sponsor with a copy of the correspondence; 
3. If the sponsor notifies about serious  adverse events reported in ot her studies using this device, 
the investigator must report that information to the EC; 
4. As required, the investigator must obtain approval from the EC  for protocol amendments and 
for revisions to the consent form or  subject recruitment  advertisements; 
5. The investigator should provide  the EC with any other inform ation it requests before or 
during conduct the study; 
6. The investigator must maintain  a file of study-related inform ation that includes all correspon-
dence with the EC; 
7. The investigator must notify EC when study is co mpleted (i.e. after the last study visit of the 
final study subject); 
8. After study completion (within 12 months is r ecommended) the investigator should provide 
the EC with a final report on the study. The recommended compone nts of a final report are as 
follows; dates of study start and completion, numbe r of subjects enrolled/treated, number of 
subjects who discontinued part icipation early and reason why, itemization and discussion of 
any serious adverse event. 
  
22. INFORMED 	CONSENT 		
 
Written informed consent must be obtained fro m each study subject. The s ubject will be asked to 
read the informed consent form and to sign the form to indicate  consent to participate in the 
study.  
The investigator will explain care fully to the subject the research  nature of the study. The scope 
and aims of the research will be  described together with known or  foreseeable benefits, risks and 
discomforts that subjects may e xperience. Appropriate alternative treatments will be  discussed so 
that the subject may determine whet her or not he or she wishes to  participate in the study.  The 
subject must understand that thr oughout the study his or her part icipation remains voluntary and 
protected by the Declaration of He lsinki.  The investigator is re sponsible for obtaining written (or 
witnessed) informed consent from  potential subjects prior to st udy entry.  Subjects will be given 
time to read the informed consent and ask any qu estions before being asked to sign the form.  
The informed consent (approved by the sponsor a nd the Ethics Committee) must be signed and 
dated by the subject and the investigator. One copy of the signed consent will be given to the 
subject, a second copy will be sent to the referral investigator and the original will be retained by 
the investigator.  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 60 of 84 
 
 
 
Subjects may withdraw their consen t to participate in the study at any time  without prejudice. 
The investigator may withdraw a subj ect if, in his clinical judgment, it is in the best interest of the 
subject or if the subject cannot comply with the protocol. Attempts should  be made to complete 
any examinations and the sponsor must  be notified of al l withdrawals.  
Should a protocol amendment be ma de, the subject's consent form may be revised to reflect the 
changes of the protocol. It is th e responsibility of the investigat or to ensure that an amended 
informed consent is approved or reviewed by the EC, and that it is signed by all subjects 
subsequently entered in the study and those curren tly in the study, if affe cted by the amendment. 
 
23. REGULATORY 	AND	HEALTH	AUTHORITY 	AUDITS	
The European Union’s authori ties and/or the Food and Drug Ad ministration (FDA) and/or the 
local state health authorities ma y request access to all study reco rds, including source documents 
for inspection. The investigator a nd hospital staff are requested to  cooperate with these audits. 
The investigator must no tify the sponsor of any health author ity audit as soon as notification of 
such audit is made. A representative or designe e of the sponsor may also  conduct similar audits 
and may be present during health authority audit. 
 
24. ELECTRONIC 	REPORTING 	OF	DATA	
 
All medical data in this trial are to be recorded  directly in the EDC (E lectronic Data Capture) 
system. Documentation on paper will be restricted to ex ceptional circumstances only. 
The investigator must ensure the accuracy, co mpleteness and timeliness (and legibility in 
case of documentation on paper) of data. 
 
Sites will get trained on how to access and use the EDC and will be foreseen with a personal user 
login and password.  
Subjects will access and complete their diaries online via a website specifically created for the 
purposes of the study. Subjects will be trained on how to access and use th is website and will be 
foreseen with a personal user login and password. 
 
 
25. RECORD 	RETENTION 	
It is required that a copy of  all records (e.g., informed cons ent documents, source documents, 
safety reports, study device dispensing record, et c.) which support case report forms for this 
study, be retained in the files of the responsible investigator for a minimum of fifteen (15) years 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 61 of 84 
 
 
 
following notification by the sponsor that all inves tigations (not merely th e investigator's portion) 
are completed, terminated and/or di scontinued.  If the principal inves tigator retires, relocates, or 
for other reasons withdraws from th e responsibility of keeping the study records, custody must be 
transferred to a person who will accept the responsi bility. Vibrant Ltd. must be notified in writing 
of the name and addre ss of the new custodian. 
26. PROTOCOL 	MODIFICATIONS 	
An amendment to the protocol may be proposed  by an investigator. The amendment will be 
prepared and approved by the sponsor according to  the sponsor’s relevant SOP. The amendment 
must be submitted to the IRB. When applicab le, the amendment’s implementation will take place 
only once approved by the IRB. 
If for any unexpected reasons, there is any requi rement to deviate from the treatments stated 
above, the protocol deviation should be disc ussed with a Vibrant Ltd. representative.  
 
27. PUBLICATION 	POLICY	
All information concerning this study that was not previously published is considered 
confidential information. This confidential inform ation shall remain the sole property of Vibrant 
Ltd.; it shall not be disclosed to  others without written consent of Vibrant Ltd. and shall not be 
used except in the perfo rmance of this study. 
Any investigator involved with th is study is obligated to provide the Sponsor with complete test 
results and all data derived from the study. 
 
28. SUBJECT 	/	STUDY	DISCONTINUATION 	
 
Subjects should be removed from the study whenever  considered necessary for their welfare or 
when the subject expresses a desire to wit hdraw from the study. N on-compliance with the 
protocol, the occurrence of a Se rious Adverse Event or any medi cal condition that, in the opinion 
of the investigator, warrants di scontinuation from the study for the safety of the subject, may 
necessitate discontinuing a subjec t. If a subject is discontinued, the reason must be entered on the 
case report form and signed by the investigator. In case of any questionable situation, the study 
monitor or Vibrant Ltd. personne l should be consulte d. When a subject is  removed from the 
study as a result of Serious Adve rse Event, a final physical ex amination must be performed. 
Subjects removed from the study because of an  adverse event will be followed-up until the 
adverse event has been resolved. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 62 of 84 
 
 
 
In the case that the occurrence of adverse even ts is greater than anticipated, the clinical 
investigation will be suspended; in such a case, a safety committee will be  arranged to decide if 
the study could be continued. The Ethics Committee wi ll be notified and the results of the safety 
committee discussions will be brought for the EC review and decision. 
 
Early termination could be a result of: 
1. Withdrawal of informed consent by the subject. 
2. Subjects who after inclusion develop medical diseases which may affect the function and 
interpretation of study results. 
3. Serious protocol deviation. 
4. Non-compliance with medical device administr ation or study proce dures as determined 
by the sponsor. 
5. Change in subject's condition. 
6. Subject is Lost to follow-up. 
7. Confirmed pregnancy. 
8. Regulatory authorities stop the trial. 
 
During the study, subjects exiting the trial will be replaced with new subjects, up to 10%  
 
Vibrant Ltd., reserves th e right to discontinue any study for administrative reasons at any time, 
such as, but not limited to a decision to discontinue  further clinical investigation with the device, 
improper conduct of the study by th e investigator, inab ility to obtain the number of subjects 
required by the protocol, etc.  Reimbursements for reasonable expenses will be made if such an 
action is necessary. 
 
29. DEVICE	ACCOUNTABILITY 		
 
Complete traceability records will be kept of all devices during the study. Vibrant devices and 
relevant accessories will be provided by Vi brant Ltd., bearing re quired labeling. Device 
identification and accessory identification will be documented in subject medical records, CRF and 
in center log. 
 
Each clinical investigator will be responsible fo r the safe storage with restricted access of the 
investigational materials in their possession, th ereby preventing use of any materials by any 
persons not participating in the study. 
All base units and remaining capsules (untouched or  taken out of the blis ter package) must be 
brought back by the subjects to the site by the time they exit the study. The number of remaining 
capsules must match the informati on transmitted by the base unit a bout capsule activations and the 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 63 of 84 
 
 
 
information gathered about  the subject’s treatmen t compliance throughout the study. In order to 
perform this task, the Sponsor, CRO  and study coordinator will rely on the same platform used to 
monitor protocol deviations related to treatmen t compliance.  A final account, and the whereabouts 
of each capsule provided to the subject will be documented in the EDC by the study coordinator. 
Capsule failures will not be documented in the EDC but on the external platform, using the base 
unit information. 
 
After completion of the study, all un used or remaining devices must be returned in their original 
package to Vibrant Ltd. Hakocha v, Yokneam 2069206 P.O.Box 516, Israel. 
All investigators will be respons ible for using the produc ts according to the IFU and protocol and 
maintaining product inve ntory and records. 
 
30. APPENDICES 	
A. Appendix A – Bristol Stool Scale 
B. Appendix B - Rome III questionnaire and instructions for completion 
C. Appendix C – Ease of use questionnaire 
D. Appendix D - Subject daily diary 
E. Appendix E – Patient Assessment of  Constipation Quality of Life (PAC-QOL) 
Questionnaire 
F. Appendix F – TSQM questionnaire  
31. REFERENCES 		
 
1. American College of Gastroenterology Chr onic Constipation Task Force. An evidence-
based approach to the management of chr onic constipation in North America. Am J 
Gastroenterol. 2005;100 Suppl 1:S1–4. 
2. Wilson N, Schey R. Lubiprostone in constipa tion: clinical evidence and place in therapy. 
Ther Adv Chronic Dis. 2015 Mar;6(2):40–50. 
3. Johanson JF, Kralstein J. Chronic constipation: a survey of the subject perspective. Aliment 
Pharmacol Ther. 2007 Mar 1;25(5):599–608. 
4. Rome III Diagnostic Criteria [Internet].  [Accessed 2015 Nov 3]. Available from: 
http://www.romecriteria.org/criteria/  
5. Only 27% of European subjects with chroni c constipation are satisfied with current 
treatment options [Internet]. [A ccessed 2015 Nov 3]. Available from: 
https://www.ueg.eu/education/document-
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 64 of 84 
 
 
 
detail/?name=only_27_of_european_subjects_w ith_chronic_constipa tion_are_satisfied_w
ith_current_treatme nt_options&file=89240  
6. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Sait o YA, Schiller LR, et al. American College 
of Gastroenterology monograph on the management of irri table bowel syndrome and 
chronic idiopathic constipation. Am J Gast roenterol. 2014 Aug;109 Suppl 1:S2–26; quiz 
S27. 
7. Paré P, Fedorak RN. Systematic review of  stimulant and nonstimulant laxatives for the 
treatment of functional constipation. Can J Gastroenterol Hepatol. 2014 Nov;28(10):549–
57. 
8. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al. Two 
randomized trials of linaclotide for chro nic constipation. N Engl J Med. 2011 Aug 
11;365(6):527–36. 
9. Soubra M, Schey R. Lubiprostone for the treat ment of adult women with irritable bowel 
syndrome with constipation. Clin Med Insights Gastroente rol. 2012;5:23–30.  
10. Wald A. Severe constipation. Clin Ga stroenterol Hepatol 2005; 3: 432–5. 
11. Cheung O, Wald A. Management of pelvic fl oor disorders. Aliment Pharmacol Ther 2004; 
19: 481–95. 
12. Tack J, Müller-Lissner S, Stanghellini V, Boeckxstaens G, Kamm MA, Simren M, et al. 
Diagnosis and treatment of chronic c onstipation--a European perspective. 
Neurogastroenterol Motil Off J Eur Gast rointest Motil Soc. 2011 Aug;23(8):697–710.  
13. Do Stool Form and Frequency Correlate With  Whole-Gut and Coloni c Transit ?  Results 
From a Multicenter Study in Constipated I ndividuals and Healthy Controls [Accessed 
March 30th, 2016 
https://www.researchgate.net/publicatio n/38066000_Do_Stool_Form_and_Frequency_Co
rrelate_With_Whole-
Gut_and_Colonic_Transit_Results_From_a_Mu lticenter_Study_in_C onstipated_Individu
als_and_Healthy_Controls] 
14. T2081 Bristol Stool Form in Slow Transit C onstipation Correlates Inversely With Regional 
Colon Contractile Activity Measured by a Wireless Motility Capsule [Accessed March 
30th, 2016 http://www.gastrojournal. org/article/S0016-5085%2810%2962894-6/pdf] 
15. Stool form scale as a useful  guide to intestinal transi t time. [Accessed March 30th, 2016 
http://www.ncbi.nlm.nih.gov/pubmed/9299672] 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 65 of 84 
 
 
 
16. Atkinson MJ, Sinha A, Hass SL, et al. Valid ation of a general m easure of treatment 
satisfaction, the Treatment Satisfaction Qu estionnaire for Medica tion (TSQM), using a 
national panel study of chronic disease. H ealth Qual Life Outcomes. 2004;2:12. Those 
seeking information regarding or  permission to use the TSQM are directed to Quintiles at 
www.quintilesims.com/TSQM or TSQM@quintilesims.com 
 
 
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 66 of 84 
 
 
 
APPENDIX A – Bristol Stool Scale 
 
 
The Bristol Stool Scale:  
 
How to analyze stools: 
 Type 1:  Stools appear in separate, hard  lumps, similar to nuts. Type 
1 stools remained in the colon the lo ngest amount of time; a sure sign 
you’re constipated; most common stools. 
 Type 2:  Stools are sausage-like in appearance but lumpy. Indicate 
toxic constipation and need for intestinal cleansing 
 Type 3 (Normal):  Stools come out similar to a sausage but with 
cracks in the surface. 
 Type 4 (Normal):  Stools are smooth and so ft in the form of a 
sausage or snake. 
 Type 5:  Stools form soft blobs with clear-cut edges, and easily pass 
through the digestive system. Soft  diarrhea, it may indicate a 
possible risk for bowel disease; al so indicate you are toxic and need 
regular intestinal cleansing. 
 Type 6:  Stools have fluffy pieces with ragged edges. Considered 
mushy stools, they indicate dia rrhea; and that you are toxic and 
need regular intestinal cleansing. 
 Type 7:  Stool is mostly liquid with no solid pieces. Passed quickly 
through the colon; is indicative of  severe diarrhea  possibly as a 
result of a viral or bacterial infection. See a doctor as soon as 
possible. 
 
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 67 of 84 
 
 
 
APPENDIX B – ROME III (Questionnair e and Instructions for Completion) 
 Instructions for completion: 
Complete questions 41 to 67 only. 
 
Scoring Algorithm:  
 
Irritable Bowel Syndrome 
Diagnostic Criteria* 
Recurrent abdominal pain or discomfort at least  3 days/month in last 3 months associated with 
two or more of criteria #1– #3  below: 
Pain or discomfort at least 2–3 days/month  (question 41 > 2) 
For women, does pain occur only during menstrual bleeding?  (question 43=0 or 2) 
1. Improvement with defecation 
Pain or discomfort gets better after BM at least sometimes  (question 46 > 0) 
2. Onset associated with a cha nge in frequency of stool 
Onset of pain or discomfort associated with more stools at least sometimes (question 47 > 0), 
OR 
Onset of pain or discomfort associated with fewer stools at least sometimes (question 48 > 0) 
3. Onset associated with a change in form (appearance) of stool 
Onset of pain or discomfort associated with looser stools at least sometimes (question 49 > 
0), OR 
Onset of pain or discomfort associated with harder stools at least sometimes  (question 50 > 
0) 
* Criteria fulfilled for the last 3 months with sy mptom onset at least 6 months prior to diagnosis 
Yes. (question 45=1)  
  
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 68 of 84 
 
 
 
Functional Constipation 
Diagnostic criteria* 
1. Must include two or mo re of the following: 
a. Straining during at least 25% of defecations. At least often.  (question 54 > 1) 
b. Lumpy or hard stools at least 25% of defecations. At least often.  (question 53 > 1) 
c. Sensation of incomplete evacuation  at least 25% of defecations. At least sometimes.  (question 
55 > 0) 
d. Sensation of anorectal obstruction/blockage at least 25% of defecations. At least sometimes.  
(question 56 > 0) 
e. Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support 
of the pelvic floor). At least sometimes.  (question 57 > 0) 
f. Fewer than three defecations per week. At least often . (question 52 > 1) 
 
2. Loose stools are rarely present without the use of laxatives. 
Loose stools occur never or rarely  (question 49=0), & 
3. Insufficient criteria for IBS 
Diagnostic criteria for IBS not met 
* Criteria fulfilled for the last 3 months with symp tom onset at least 6 mont hs prior to diagnosis. 
Yes. (question 59=1) 
   
 
   
 
   
 
   
 
   
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 69 of 84 
 
 
 
APPENDIX C – Ease of use questionnaire 
 
Please	rank	the	following 	tasks	and	propositions 	on	a	scale	from	1	to	5	
(Circle the response that be st represents your opinion)  
[1] Connecting the base unit to Wi-Fi 
1	 2	 3	 4	 5		
Very Hard Hard Medium Easy Very Easy  
[2] Setting up the base unit for use 
1	 2	 3	 4	 5		
Very Hard Hard Medium Easy Very Easy  
[3] Activating capsules 
1	 2	 3	 4	 5		
Very Hard Hard Medium Easy Very Easy  
[4] Knowing if the capsules have been successfully activated or not 
1	 2	 3	 4	 5		
Very Hard Hard Medium Easy Very Easy  
[5] Following the treatment for several mo nths once it is commercialized (there 
would be no need to connect the base unit to Wi-Fi)  
1	 2	 3	 4	 5		
Very Hard Hard Medium Easy Very Easy  
[6] How likely would you be to use the capsule if it is commercially available in the 
future?  
1	 2	 3	 4	 5		
Not at all likely Not likely Neutral Likely Very likely  
 
 
 
   
 
   
 
    
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 70 of 84 
 
 
 
APPENDIX D – Subject Diaries  
 
Subject Initials: |__|-|__|  
Subject Identification Number: |__|__|-|__|__|__|  
Name of the center/site: ___________________ 
Location of the center/site: _________________  
 
Day |__|__| of Study 
  
             Date:                          |__|__| / |__|__|__| / 20|__|__| 
                           Day              Month                 Year 
 
FORM 1: Capsules 
 
 I haven’t started treatment  
 
 I have started treatment  
If you started treatment, please specify for the day:  
 
How many capsules did you ta ke out of the blister package?    |__| 
 
How many capsules did you swallow?  |__|  
 
Comments: 
________________________ _____________________ _________________________ 
 
________________________ _____________________ _________________________ 
What is your level of sa tisfaction with the treatment? 
0          1         2      3        4          5         6        7        8        9       10                                                                                        
                                                                                                                                                         
No satisfaction                                                               Great satisfaction  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 71 of 84 
 
 
 
FORM 2: Bowel movements 
 
Please note: the diary paper form allows you to enter information about up to 3 bowel 
movement for ONE day.  
 
Number of bowel movements for the day:   |__| 
If you had at least one bowel movement today, please answer , for each bowel 
movement: 
 
BOWEL MOVEMENT 1 
 
1. Time of defecation: |__|__| :|__|__|   am/pm  
2. What was consistency of the bowel movement? 
1 = Separate hard lumps, like nuts (hard to pass) 
2 = sausage-shaped, but lumpy 
3 = like a sausage but with cracks on its surface 
4 = Like a sausage or snake, smooth and soft 
5 = Soft blobs with clear-cut edges (passed easily) 
6 = fluffy pieces with ragged edges, a mushy stool 
7 = watery, no solid pieces, entirely liquid 
3. Were you left with a feeling of complete evacuation?        Yes    No 
4. How much straining was needed to have the bowel movement? 
        0  1 2 3 4 5 6 7 8 9 10  
           
No straining                                                                              
Unbearable straining 
 
  
5. Did you use digital maneuver in order to have the bowel movement?  Yes   No 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 72 of 84 
 
 
 
 
 
BOWEL MOVEMENT 2 
 
1. Time of defecation: |__|__| :|__|__|   am/pm  
2. What was consistency of the bowel movement? 
1 = Separate hard lumps, like nuts (hard to pass) 
2 = sausage-shaped, but lumpy 
3 = like a sausage but with cracks on its surface 
4 = Like a sausage or snake, smooth and soft 
5 = Soft blobs with clear-cut edges (passed easily) 
6 = fluffy pieces with ragged edges, a mushy stool 
7 = watery, no solid pieces, entirely liquid 
3. Were you left with a feeling of complete evacuation?        Yes    No 
4. How much straining was needed to have the bowel movement? 
        0  1 2 3 4 5 6 7 8 9 10  
           
No straining                                                                              
Unbearable straining 
 
  
5. Did you use digital maneuver in order to have the bowel movement?  Yes   No 
 
 
 
 
 
 
 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 73 of 84 
 
 
 
BOWEL MOVEMENT 3 
 
1. Time of defecation: |__|__| :|__|__|   am/pm  
2. What was consistency of the bowel movement? 
1 = Separate hard lumps, like nuts (hard to pass) 
2 = sausage-shaped, but lumpy 
3 = like a sausage but with cracks on its surface 
4 = Like a sausage or snake, smooth and soft 
5 = Soft blobs with clear-cut edges (passed easily) 
6 = fluffy pieces with ragged edges, a mushy stool 
7 = watery, no solid pieces, entirely liquid 
3. Were you left with a feeling of complete evacuation?        Yes    No 
4. How much straining was needed to have the bowel movement? 
        0  1 2 3 4 5 6 7 8 9 10  
           
No straining                                                                       
Unbearable straining 
 
  
5. Did you use digital maneuver in order to have the bowel movement?  Yes   No 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 74 of 84 
 
 
 
 
FORM 3: daily experience 
 
Please score your experience today, wh ether you had a bowel movement or not  
1. What is your level of abdominal pain for the day? 
        0  1 2 3 4 5 6 7 8 9 10  
           
No pain                                                                     
Unbearable pain 
 
 
2. What is your level of abdominal discomfort for the day? 
        0  1 2 3 4 5 6 7 8 9 10  
           
No discomfort                                                                       
Unbearable discomfort 
 
 
3. What is your level of bloating for the day? 
        0  1 2 3 4 5 6 7 8 9 10  
           
No abdominal gas                                                                    
Unbearable abdominal gas  
 
 
4. What is your level of abdominal gas for the day? 
        0  1 2 3 4 5 6 7 8 9 10  
           
No bloating                                            
Unbearable bloating 
 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 75 of 84 
 
 
 
 
 
 
 
Has there been any change to your  general health condition?        Yes    No 
If yes, please detail:  
________________________ __________________ _____________________ ______________ 
________________________ __________________ _____________________ ______________ 
________________________ __________________ _____________________ ______________ 
________________________ __________________ _____________________ ______________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 76 of 84 
 
 
 
 
 
 
FORM 4: rescue medication 
 
Have you taken any rescue medication?                                 Yes    No 
If yes, please detail be low the name and dosage 
 
 
 
FORM 5: other medication 
Have you taken any other medicat ion/supplements?          Yes    No Name of drug Dosage Unit Time of the intake Number of 
takes/day Comments 
   |__|__| :|__|__|  am/pm     
   |__|__| :|__|__|  am/pm     
If yes, please detail below the name and reason for intake 
Name of drug Dosage Unit Number of 
takes/day Reason Comments 
      
      
      
      
      
 
 
 
 
 
     
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 77 of 84 
 
 
 
 APPENDIX E – Patient Assessment of Constipati on Quality of Life (PAC-QOL) Questionnaire  
 
The following questions are designed to measure th e impact constipation has had on your daily life over the past 2 weeks . For each question, please check 
one box. 
The following questions ask about your symp toms related to constipation. During the 
past 2 weeks, to what extent or intensity have you . . . Not at all 
1 A little bit 
2 Moderately 
3 Quite a bit 
4 Extremely 
5 
1. Felt bloated to the point of bursting? ☐ ☐ ☐ ☐ ☐ 
2. Felt heavy because of your constipation? ☐ ☐ ☐ ☐ ☐ 
The next few questions ask about how constipa tion affects your daily life. During the 
past 2 weeks, how much of the time have you . . . None of 
the time 
1 A little of 
the time 
2 Some of 
the time 
3 Most of the 
time 
4 All of the 
time 
5 
3. Felt any physical discomfort? ☐ ☐ ☐ ☐ ☐ 
4. Felt the need to have a bowel movement but not been able to? ☐ ☐ ☐ ☐ ☐ 
5. Been embarrassed to be with other people? ☐ ☐ ☐ ☐ ☐ 
6. Been eating less and less because of not being able to have bowel movements? ☐ ☐ ☐ ☐ ☐ 
The next few questions ask about how constipa tion affects your daily life. During the 
past 2 weeks, to what extent or intensity have you . . . Not at all 
1 A little bit 
2 Moderately 
3 Quite a bit 
4 Extremely 
5 
7. Had to be careful about what you eat?  ☐ ☐ ☐ ☐ ☐ 
8. Had a decreased appetite?  ☐ ☐ ☐ ☐ ☐ 
9. Been worried about not being able to ch oose what you eat (for example, at a 
friend’s house)? ☐ ☐ ☐ ☐ ☐ 
10. Been embarrassed about staying in the bathroom for so long when you were 
away from home? ☐ ☐ ☐ ☐ ☐ 
11. Been embarrassed about having to go to the bathroom so often when you 
were away from home? ☐ ☐ ☐ ☐ ☐ 
12. Been worried about having to change your daily routine (for example, 
traveling, being away from home)? ☐ ☐ ☐ ☐ ☐ 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 78 of 84 
 
 
 
The next few questions ask about your feeli ngs related to constipation. During the past 
2 weeks, how much of the time have you . . . None of 
the time 
1 A little of 
the time 
2 Some of 
the time 
3 Most of the 
time 
4 All of the 
time 
5 
13. Felt irritable because of your condition?  ☐ ☐ ☐ ☐ ☐ 
14. Been upset by your condition?  ☐ ☐ ☐ ☐ ☐ 
15. Felt obsessed by your condition?  ☐ ☐ ☐ ☐ ☐ 
16. Felt stressed by your condition?  ☐ ☐ ☐ ☐ ☐ 
17. Felt less self-confident because of your condition?  ☐ ☐ ☐ ☐ ☐ 
18. Felt in control of your situation?  ☐ ☐ ☐ ☐ ☐ 
The next questions ask about your feelings related to constipation. During the past 2 
weeks, to what extent or intensity have you . . . Not at all 
1 A little bit 
2 Moderately 
3 Quite a bit 
4 Extremely 
5 
19. Been worried about not knowing when yo u are going to be able to have a 
bowel movement? ☐ ☐ ☐ ☐ ☐ 
20. Been worried about not being able to have a bowel movement? ☐ ☐ ☐ ☐ ☐ 
21. Been increasingly bothered by not being able to have a bowel movement? ☐ ☐ ☐ ☐ ☐ 
The next questions ask about your life with constipation. During the past 2 weeks, how 
much of the time have you . . . 
 None of 
the time 
1 A little of 
the time 
2 Some of 
the time 
3 Most of the 
time 
4 All of the 
time 
5 
22. Been worried that your co ndition will get worse?  ☐ ☐ ☐ ☐ ☐ 
23. Felt that your body was not working properly?  ☐ ☐ ☐ ☐ ☐ 
24. Had fewer bowel movements than you would like? ☐ ☐ ☐ ☐ ☐ 
The next questions ask about your degree of  satisfaction related to constipation. 
During the past 2 weeks, to what extent or intensity have you been . . . Not at all 
1 A little bit 
2 Moderately 
3 Quite a bit 
4 Extremely 
5 
25. Satisfied with how often you have a bowel movement?  ☐ ☐ ☐ ☐ ☐ 
26. Satisfied with the regularity of your bowel movements?  ☐ ☐ ☐ ☐ ☐ 
27. Satisfied with the time it takes for food to pass through the intestines? ☐ ☐ ☐ ☐ ☐ 
28. Satisfied with your treatment? ☐ ☐ ☐ ☐ ☐ 
 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 79 of 84 
 
 
 
 
APPENDIX F– TSQM Questionnaire  
TSQM  (Version 1.4)  
Treatment Satisfaction Questionnaire for Medication 
 
Instructions:  Please take some time to th ink about your level of satisfaction or 
dissatisfaction with the treat ment you are taking in this  clinical trial.  We are 
interested in your evaluati on of the effectiveness, side effects, and convenience of 
the treatment over the last two to three w eeks, or since you last used it .  For each 
question, please place a single check mark next  to the response that most closely 
corresponds to your own experiences.  
 
1. How satisfied or dissatisfied are you with the ability of the treatment to prevent or treat your 
condition?  
 
□1   Extremely Dissatisfied 
□2   Very Dissatisfied 
□3   Dissatisfied 
□4   Somewhat Satisfied 
□5   Satisfied 
□6   Very Satisfied 
□7   Extremely Satisfied 
 
2. How satisfied or dissatisfied are you with th e way the treatment relieves your symptoms?  
 
□1   Extremely Dissatisfied 
□2   Very Dissatisfied 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 80 of 84 
 
 
 
□3   Dissatisfied 
□4   Somewhat Satisfied 
□5   Satisfied 
□6   Very Satisfied 
□7   Extremely Satisfied 
 
3. How satisfied or dissatisfied are you with the amount of time it takes the treatment to start 
working?  
 
□1   Extremely Dissatisfied 
□2   Very Dissatisfied 
□3   Dissatisfied 
□4   Somewhat Satisfied 
□5   Satisfied 
□6   Very Satisfied 
□7   Extremely Satisfied  
 
 
4.  As a result of taking this treatment, do you experience any side effects at all? 
 
□1   Yes 
□0   No  (if No, then please skip to Question 9) 
 
 
5. How bothersome are the side effects of the treatment you take to tr eat your condition?  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 81 of 84 
 
 
 
 
□1   Extremely Bothersome 
□2   Very Bothersome 
□3   Somewhat Bothersome 
□4   A Little Bothersome  
□5   Not at All Bothersome 
 
6. To what extent do the side e ffects interfere with your physica l health and ability to function 
(i.e., strength, energy levels, etc.)?  
 
□1   A Great Deal 
□2   Quite a Bit 
□3   Somewhat 
□4   Minimally 
□5   Not at All 
 
7. To what extent do the side e ffects interfere with your mental function (i.e., ability to think 
clearly, stay awake, etc.)?  
 
□1   A Great Deal 
□2   Quite a Bit 
□3   Somewhat 
□4   Minimally 
□5   Not at All 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 82 of 84 
 
 
 
8. To what degree have treatment side effects affected your overall satisfaction with the 
treatment?  
 
□1   A Great Deal 
□2   Quite a Bit 
□3   Somewhat 
□4   Minimally 
□5   Not at All 
 
9. How easy or difficult is it to us e the treatment in its current form?  
 
□1   Extremely Difficult 
□2   Very Difficult 
□3   Difficult 
□4   Somewhat Easy 
□5   Easy 
□6   Very Easy 
□7   Extremely Easy 
 
10. How easy or difficult is it to plan when you will use the treatment each time?  
 
□1   Extremely Difficult 
□2   Very Difficult 
□3   Difficult 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 83 of 84 
 
 
 
□4   Somewhat Easy 
□5   Easy 
□6   Very Easy 
□7   Extremely Easy 
 
11. How convenient or inconvenient is it  to take the treatment as instructed?  
 
□1   Extremely Inconvenient 
□2   Very Inconvenient 
□3   Inconvenient 
□4   Somewhat Convenient 
□5   Convenient 
□6   Very Convenient  
□7   Extremely Convenient 
 
 
12. Overall, how confident are you that taking this treatment is a good thing for you?  
 
□1   Not at All Confident 
□2   A Little Confident 
□3   Somewhat Confident 
□4   Very Confident  
□5   Extremely Confident 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-250 Doc No: 250CLD  
Rev: 02Date: 07 Oct 2018 
Page 84 of 84 
 
 
 
13. How certain are you that the good things ab out your treatment outweigh the bad things?  
 
□1   Not at All Certain 
□2   A Little Certain 
□3   Somewhat Certain 
□4   Very Certain 
□5   Extremely Certain 
 
14. Taking all things into account, how satisfied or dissatisfied are you with this treatment?  
 
□1   Extremely Dissatisfied 
□2   Very Dissatisfied 
□3   Dissatisfied 
□4   Somewhat Satisfied 
□5   Satisfied 
□6   Very Satisfied  
□7   Extremely Satisfied 
 
 
 
Copyright Quintiles 2017. All rights reserved.  
  
 
   